Diagnostic,O
accuracy,O
of,O
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
:,O
systematic,O
Mayara,PERSON
Lisboa,PERSON
Bastos,PERSON
.1.2,O
Gamuchirai,PERSON
Tavaziva,PERSON
.1,O
Syed,PERSON
Kunal,PERSON
Abidi,PERSON
.1,O
Jonathon,PERSON
R,PERSON
Campbell,PERSON
.1.6,O
Louis,PERSON
‐,O
Patrick,PERSON
Haraoui,PERSON
.3,NUMBER
James,PERSON
C,PERSON
John,PERSON
‐,PERSON
ston,O
.4,NUMBER
Zhiyi,PERSON
Lan,PERSON
.1,O
Stephanie,PERSON
Law,PERSON
.5,NUMBER
Emily,PERSON
MacLean,PERSON
.6,O
Anete,O
Traj,O
‐,O
man,O
.1.2,NUMBER
Dick,PERSON
Menzies,PERSON
.1.6,O
Andrea,PERSON
Benedetti,PERSON
.1.6,O
Faiz,PERSON
Ahmad,PERSON
Khan1,O
.6,O
Respiratory,ORGANIZATION
Epidemiology,ORGANIZATION
and,ORGANIZATION
Clinical,ORGANIZATION
Research,ORGANIZATION
Unit,ORGANIZATION
.,O
Centre,O
for,O
Outcomes,ORGANIZATION
Research,ORGANIZATION
and,ORGANIZATION
Centre,ORGANIZATION
.,O
Montreal,CITY
.,O
Canada,COUNTRY
de,LOCATION
Janeiro,LOCATION
.,O
Brazil,COUNTRY
Department,ORGANIZATION
of,ORGANIZATION
Microbiology,ORGANIZATION
and,O
Infectious,O
Diseases,CAUSE_OF_DEATH
.,O
Faculty,O
of,O
Medicine,O
and,O
Health,ORGANIZATION
Sciences,ORGANIZATION
.,O
Universit,ORGANIZATION
de,ORGANIZATION
Sherbrooke,ORGANIZATION
.,O
Sher,PERSON
‐,PERSON
brooke,O
.,O
Qubec,LOCATION
.,O
Canada,COUNTRY
Vancouver,CITY
.,O
Canada,ORGANIZATION
Department,ORGANIZATION
of,ORGANIZATION
Global,ORGANIZATION
Health,O
and,O
Social,ORGANIZATION
Medicine,ORGANIZATION
.,O
Harvard,ORGANIZATION
Departments,ORGANIZATION
of,ORGANIZATION
Epidemiology,ORGANIZATION
.,O
Biostatistics,O
and,O
Occupational,ORGANIZATION
Health,ORGANIZATION
.,O
and,O
Medicine,O
.,O
McGill,ORGANIZATION
Cor,O
‐,O
respondence,O
to,O
:,O
F,PERSON
Ahmad,PERSON
Khan,PERSON
Cite,O
this,O
as,O
:,O
BMJ2020,O
;,O
370,NUMBER
:,O
m2516,O
To,O
determine,O
the,O
diagnostic,O
accuracy,O
of,O
serological,O
tests,O
for,O
coron,O
‐,O
avirus,O
disease,CAUSE_OF_DEATH
‐,O
2019,DATE
(,O
covid,O
‐,O
19,NUMBER
),O
.,O
Data,O
sources,O
Medline,ORGANIZATION
.,O
bioRxiv,O
.,O
and,O
medRxiv,O
from,O
1,DATE
January,DATE
to,O
30,DATE
April,DATE
2020,DATE
.,O
using,O
subject,O
head,O
‐,O
ings,O
or,O
subheadings,O
combined,O
with,O
text,O
words,O
for,O
the,O
concepts,O
of,O
covid,O
‐,O
19,NUMBER
and,O
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
.,O
Eligibility,O
crite,O
‐,O
ria,O
and,O
data,O
analysis,O
Eligible,O
studies,O
measured,O
sensitivity,O
or,O
specificity,O
.,O
or,O
both,O
of,O
a,O
covid,O
‐,O
19,NUMBER
serological,O
test,O
compared,O
with,O
a,O
reference,O
standard,O
of,O
viral,O
culture,O
or,O
reverse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
.,O
Studies,O
were,O
excluded,O
with,O
fewer,O
than,O
five,NUMBER
participants,O
or,O
samples,O
.,O
Risk,O
of,O
bias,O
was,O
assessed,O
using,O
quality,O
assessment,O
of,O
diagnostic,O
accuracy,O
studies,O
2,NUMBER
(,O
QUADAS,O
‐,O
2,NUMBER
),O
.,O
Pooled,O
sensitivity,O
and,O
specificity,O
were,O
estimated,O
using,O
random,O
effects,O
bivariate,O
meta,O
‐,O
analyses,O
.,O
Main,O
outcome,O
measures,O
The,O
pri,O
‐,O
mary,O
outcome,O
was,O
overall,O
sensitivity,O
and,O
specificity,O
.,O
stratified,O
by,O
method,O
of,O
serological,O
testing,O
(,O
enzyme,O
linked,O
immunosorbent,O
as,O
‐,O
says,O
(,O
ELISAs,O
),O
.,O
lateral,O
flow,O
immunoassays,O
(,O
LFIAs,O
),O
.,O
or,O
chemilumi,O
‐,O
nescent,O
immunoassays,O
(,O
CLIAs,O
),O
),O
and,O
immunoglobulin,O
class,O
(,O
IgG,O
.,O
IgM,O
.,O
or,O
both,O
),O
.,O
Secondary,O
outcomes,O
were,O
stratum,O
specific,O
sensitivity,O
and,O
specificity,O
within,O
subgroups,O
defined,O
by,O
study,O
or,O
What,O
is,O
al,O
‐,O
ready,O
known,O
on,O
this,O
topic,O
Serological,MISC
tests,O
to,O
detect,O
antibodies,O
against,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
‐,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
could,O
improve,O
diagnosis,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
covid,O
‐,O
19,NUMBER
),O
and,O
be,O
useful,O
tools,O
for,O
epidemiological,O
surveillance,O
The,O
number,O
of,O
serological,O
tests,O
has,O
rapidly,O
increased,O
.,O
and,O
many,O
are,O
being,O
marketed,O
for,O
point,O
‐,O
of,O
‐,O
care,O
use,O
The,O
evidence,O
base,O
sup,O
‐,O
porting,O
the,O
diagnostic,O
accuracy,O
of,O
these,O
tests,O
.,O
however,O
.,O
has,O
not,O
been,O
formally,O
evaluated,O
What,O
this,O
study,O
adds,O
The,O
available,O
evi,O
‐,O
dence,O
on,O
the,O
accuracy,O
of,O
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
is,O
char,O
‐,O
acterised,O
by,O
risks,O
of,O
bias,O
and,O
heterogeneity,O
.,O
and,O
as,O
such,O
.,O
esti,O
‐,O
mates,O
of,O
sensitivity,O
and,O
specificity,O
are,O
unreliable,O
and,O
have,O
lim,O
‐,O
ited,O
generalisability,O
Evidence,O
is,O
particularly,O
weak,O
for,O
point,O
‐,O
of,O
‐,O
care,O
serological,O
tests,O
Caution,O
is,O
warranted,O
if,O
using,O
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
for,O
clinical,O
decision,O
making,O
or,O
epidemiologi,O
‐,O
cal,O
surveillance,O
Current,DATE
evidence,O
does,O
not,O
support,O
the,O
continued,O
use,O
of,O
existing,O
point,O
‐,O
of,O
‐,O
care,O
participant,O
characteristics,O
.,O
in,O
‐,O
cluding,O
time,O
since,O
symptom,O
onset,O
.,O
5016,NUMBER
references,O
were,O
identi,O
‐,O
fied,O
and,O
40,NUMBER
studies,O
included,O
.,O
49,NUMBER
risk,O
of,O
bias,O
assessments,O
were,O
carried,O
out,O
(,O
one,NUMBER
for,O
each,O
population,O
and,O
method,O
evaluated,O
),O
.,O
High,O
risk,O
of,O
patient,O
selection,O
bias,O
was,O
found,O
in,O
98,PERCENT
%,PERCENT
(,O
48/49,NUMBER
),O
of,O
as,O
‐,O
sessments,O
and,O
high,O
or,O
unclear,O
risk,O
of,O
bias,O
from,O
performance,O
or,O
interpretation,O
of,O
the,O
serological,O
test,O
in,O
73,PERCENT
%,PERCENT
(,O
36/49,NUMBER
),O
.,O
Only,O
10,PERCENT
%,PERCENT
(,O
4/40,NUMBER
),O
of,O
studies,O
included,O
outpatients,O
.,O
Only,O
two,NUMBER
studies,O
evaluat,O
‐,O
ed,O
tests,O
at,O
the,O
point,O
of,O
care,O
.,O
For,O
each,O
method,O
of,O
testing,O
.,O
pooled,O
sensitivity,O
and,O
specificity,O
were,O
not,O
associated,O
with,O
the,O
im,O
‐,O
munoglobulin,O
class,O
measured,O
.,O
The,O
pooled,O
sensitivity,O
of,O
ELISAs,O
measuring,O
IgG,O
or,O
IgM,O
was,O
84.3,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
confidence,O
interval,O
75.6,PERCENT
%,PERCENT
to,O
90.9,PERCENT
%,PERCENT
),O
.,O
of,O
LFIAs,O
was,O
66.0,PERCENT
%,PERCENT
(,O
49.3,PERCENT
%,PERCENT
to,O
79.3,PERCENT
%,PERCENT
),O
.,O
and,O
of,O
CLIAs,O
was,O
97.8,PERCENT
%,PERCENT
(,O
46.2,PERCENT
%,PERCENT
to,O
100,PERCENT
%,PERCENT
),O
.,O
In,O
all,O
analyses,O
.,O
pooled,O
sensitivity,O
was,O
lower,O
for,O
LFIAs,O
.,O
the,O
potential,O
point,O
‐,O
of,O
‐,O
care,O
method,O
.,O
Pooled,O
specificities,O
ranged,O
from,O
96.6,PERCENT
%,PERCENT
to,O
99.7,PERCENT
%,PERCENT
.,O
Of,O
the,O
samples,O
used,O
for,O
estimating,O
specificity,O
.,O
83,PERCENT
%,PERCENT
(,O
10 465/12,O
547,NUMBER
),O
were,O
from,O
populations,O
tested,O
before,O
the,O
epidemic,O
or,O
not,O
suspected,O
of,O
having,O
covid,O
‐,O
19,NUMBER
.,O
Among,O
LFIAs,O
.,O
pooled,O
(,O
88.2,PERCENT
%,PERCENT
.,O
83.6,PERCENT
%,PERCENT
to,O
91.3,PERCENT
%,PERCENT
),O
.,O
Heterogeneity,O
was,O
seen,O
in,O
all,O
analyses,O
.,O
Sensitivity,O
was,O
higher,O
at,DURATION
least,DURATION
three,DURATION
weeks,DURATION
after,O
symptom,O
onset,O
(,O
ranging,O
from,O
69.9,PERCENT
%,PERCENT
to,O
98.9,PERCENT
%,PERCENT
),O
compared,O
with,O
within,O
the,DURATION
first,DURATION
week,DURATION
(,O
from,O
Higher,O
quality,O
clinical,O
studies,O
as,O
‐,O
sessing,O
the,O
diagnostic,O
accuracy,O
of,O
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
are,O
urgently,O
needed,O
.,O
Currently,DATE
.,O
available,O
evidence,O
does,O
not,O
sup,O
‐,O
port,O
the,O
continued,O
use,O
of,O
existing,O
pointof,O
‐,O
care,O
serological,O
tests,O
.,O
Study,O
registration,O
PROSPERO,O
CRD42020179452,O
.,O
Accurate,O
and,O
rapid,O
diagnostic,O
tests,O
will,O
be,O
critical,O
for,O
achieving,O
control,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
covid,O
‐,O
19,NUMBER
),O
.,O
a,O
pandemic,O
illness,CAUSE_OF_DEATH
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARSCoV,O
‐,O
2,NUMBER
),O
.,O
Di,O
‐,O
agnostic,RELIGION
tests,O
for,O
covid,O
‐,O
19,NUMBER
fall,DATE
into,O
two,NUMBER
main,O
categories,O
:,O
molec,O
‐,O
ular,O
tests,O
that,O
detect,O
viral,O
RNA,MISC
.,O
and,O
serological,O
tests,O
that,O
de,O
‐,O
tect,O
anti,O
‐,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
immunoglobulins,O
.,O
Reverse,O
transcriptase,O
poly,O
‐,O
merase,O
chain,O
reaction,O
(,O
RT,O
‐,O
PCR,O
),O
.,O
a,O
molecular,O
test,O
.,O
is,O
widely,O
used,O
as,O
the,O
reference,O
standard,O
for,O
diagnosis,O
of,O
covid,O
‐,O
19,NUMBER
;,O
however,O
.,O
limitations,O
include,O
potential,O
false,O
negative,O
results,O
.1,O
2,NUMBER
changes,O
in,O
diagnostic,O
accuracy,O
over,O
the,O
disease,CAUSE_OF_DEATH
course,O
.3,O
and,O
precarious,O
availability,O
of,O
test,O
materials,O
.4,NUMBER
Serological,O
tests,O
have,O
generated,O
substantial,O
interest,O
as,O
an,O
alternative,O
or,O
complement,O
to,O
RT,O
‐,O
PCR,O
in,O
the,O
diagnosis,O
of,O
acute,O
infection,CAUSE_OF_DEATH
.,O
as,O
some,O
might,O
be,O
cheaper,O
and,O
easier,O
to,O
implement,O
at,O
the,O
point,O
of,O
care,O
.,O
A,O
clear,O
advantage,O
of,O
these,O
tests,O
over,O
RT,O
‐,O
PCR,O
is,O
that,O
they,O
can,O
identify,O
individuals,O
previously,DATE
infected,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
even,O
if,O
they,O
never,O
underwent,O
testing,O
while,O
acutely,O
ill,O
.,O
As,O
such,O
.,O
serological,O
tests,O
could,O
be,O
deployed,O
as,O
surveillance,O
tools,O
to,O
better,O
understand,O
the,O
epidemi,O
‐,O
ology,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
and,O
potentially,O
inform,O
individual,O
risk,O
of,O
fu,O
‐,O
ture,O
disease,CAUSE_OF_DEATH
.,O
Many,O
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
have,O
become,O
available,O
in,O
a,O
short,O
period,O
.,O
including,O
some,O
marketed,O
for,O
use,O
as,O
rapid,O
.,O
point,O
‐,O
of,O
‐,O
care,O
tests,O
.,O
The,O
pace,O
of,O
development,O
has,O
.,O
however,O
.,O
exceeded,O
that,O
of,O
rigorous,O
evaluation,O
.,O
and,O
important,O
uncertainty,O
about,O
test,O
accuracy,O
remains,O
.5,NUMBER
to,O
assess,O
the,O
diagnostic,O
accuracy,O
of,O
serological,O
tests,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
Our,O
objectives,O
were,O
to,O
evaluate,O
the,O
quality,O
of,O
the,O
available,O
evidence,O
.,O
to,O
com,O
‐,O
pare,O
pooled,O
sensitivities,O
and,O
specificities,O
of,O
different,O
test,O
methods,O
.,O
and,O
to,O
identify,O
study,O
.,O
test,O
.,O
and,O
patient,O
characteristics,O
associated,O
with,O
test,O
accuracy,O
.,O
Search,O
strategy,O
and,O
selection,O
criteria,O
according,O
to,O
the,O
preferred,O
reporting,O
items,O
for,O
systemat,O
‐,O
ic,O
(,O
see,O
supplementary,O
file,O
),O
.,O
We,O
searched,O
Ovid,LOCATION
‐,O
Medline,O
Covid,O
‐,O
19,NUMBER
antibody,O
testing,O
Visual,O
Abstract,O
Current,DATE
evidence,O
does,O
not,O
sup,O
‐,O
port,O
the,O
continued,O
use,O
of,O
existing,O
point,O
‐,O
of,O
‐,O
care,O
covid,O
‐,O
serology,O
tests,O
with,O
the,O
LFIA,O
method,O
.,O
Only,O
two,NUMBER
studies,O
evaluated,O
perfor,O
‐,O
mance,O
at,O
the,O
point,O
of,O
care,O
Study,O
design,O
Data,O
sources,O
Sensitivity,O
estimated,O
from,O
people,O
with,O
confirmed,O
covid,O
‐,O
Specificity,O
estimated,O
mostly,O
using,O
pre,O
‐,O
epidemic,O
samples,O
.,O
or,O
low,O
risk,O
individuals,O
More,O
than,O
one,NUMBER
sample,O
may,O
have,O
originated,O
from,O
the,O
same,O
participant,O
En,O
‐,O
zyme,O
Linked,O
Lateral,O
Flow,O
TRUE,O
result,O
Under,PERCENT
%,PERCENT
prevalence,O
FALSE,O
re,O
‐,O
sult,O
Patients,O
with,O
Patients,O
without,O
Evidence,O
quality,O
Evidence,O
about,O
the,O
diagnostic,O
accuracy,O
of,O
covid,O
‐,O
serology,O
tests,O
is,O
charac,O
‐,O
terised,O
by,O
high,O
risks,O
of,O
bias,O
.,O
heterogeneity,O
.,O
and,O
limited,O
gener,O
‐,O
alisability,O
to,O
point,O
‐,O
of,O
‐,O
care,O
testing,O
and,O
to,O
outpatient,O
popula,O
‐,O
tions,O
Diagnostic,MISC
accuracy,O
of,O
three,NUMBER
serological,O
tests,O
on,O
language,O
.,O
Subject,O
headings,O
/,O
subheadings,O
(,O
when,O
applicable,O
),O
combined,O
with,O
text,O
words,O
were,O
used,O
for,O
the,O
concepts,O
of,O
covid,O
‐,O
19,NUMBER
(,O
or,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
and,O
serological,O
tests,O
.,O
The,O
supplementary,O
file,O
provides,O
the,O
complete,O
search,O
strategy,O
.,O
run,O
on,O
6,DATE
April,DATE
2020,DATE
list,O
of,O
covid,O
‐,O
19,NUMBER
preprints,O
from,O
medRxiv,O
and,O
bioRxiv,O
initially,O
on,O
4,DATE
April,DATE
2020,DATE
.,O
and,O
again,O
on,O
28,DATE
April,DATE
2020,DATE
.,O
identified,O
in,O
references,O
of,O
included,O
studies,O
.,O
Eligible,O
studies,O
were,O
randomised,O
trials,O
.,O
cohort,O
or,O
case,O
‐,O
control,O
studies,O
.,O
and,O
case,O
series,O
.,O
reporting,O
the,O
sensitivity,O
or,O
specifici,O
‐,O
ty,O
.,O
or,O
both,O
of,O
a,O
serological,O
test,O
with,O
sample,O
sizes,O
less,O
than,O
five,NUMBER
.,O
and,O
studies,O
that,O
only,O
reported,O
analytical,O
sensitivity,O
(,O
ie,O
.,O
dilutional,O
identification,O
of,O
detection,O
limits,O
),O
.7,NUMBER
Three,NUMBER
investiga,O
‐,O
tors,O
(,O
MB,STATE_OR_PROVINCE
.,O
GT,O
.,O
FAK,O
),O
independently,O
screened,O
titles,O
and,O
abstracts,O
.,O
and,O
two,NUMBER
(,O
MB,STATE_OR_PROVINCE
.,O
GT,O
),O
independently,O
screened,O
full,O
text,O
papers,O
.,O
We,O
used,O
a,O
sensitive,O
screening,O
strategy,O
at,O
the,O
title,O
or,O
abstract,O
level,O
wherein,O
selection,O
by,O
a,O
included,O
studies,O
when,O
sensitivity,O
or,O
specificity,O
.,O
or,O
both,O
of,O
at,O
least,O
one,NUMBER
covid,O
‐,O
19,NUMBER
serological,O
test,O
was,O
measured,O
against,O
a,O
reference,O
standard,O
of,O
viral,O
culture,O
or,O
RT,O
‐,O
PCR,O
.,O
Data,O
analysis,O
In,O
our,O
primary,O
analysis,O
.,O
we,O
estimated,O
pooled,O
sensitivity,O
and,O
specificity,O
by,O
method,O
of,O
serological,O
test,O
.,O
We,O
ex,O
‐,O
pected,O
that,O
accuracy,O
would,O
be,O
associated,O
with,O
the,O
immunoglobulin,O
class,O
being,O
measured,O
.,O
as,O
is,O
the,O
case,O
for,O
other,O
coronaviruses,O
.8,NUMBER
‐,O
10,NUMBER
As,O
such,O
.,O
we,O
stratified,O
the,O
primary,O
results,O
by,O
class,O
of,O
im,O
‐,O
munoglobulin,O
detected,O
.,O
One,NUMBER
investigator,TITLE
(,O
MB,STATE_OR_PROVINCE
),O
extracted,O
aggregate,O
study,O
level,O
data,O
using,O
a,O
piloted,O
standardised,O
electronic,O
(,O
ZL,O
or,O
EM,O
),O
verified,O
all,O
entered,O
data,O
.,O
No,O
duplicate,O
data,O
were,O
identified,O
.,O
We,O
collected,O
information,O
on,O
study,O
characteristics,O
(,O
location,O
.,O
de,O
‐,O
sign,O
),O
.,O
study,O
populations,O
(,O
age,O
.,O
sex,O
.,O
clinical,O
severity,O
.,O
sources,O
of,O
populations,O
used,O
for,O
estimating,O
specificity,O
),O
.,O
the,O
timing,O
of,O
spec,O
‐,O
imen,O
collection,O
in,O
relation,O
to,O
onset,O
of,O
symptoms,O
.,O
and,O
methodolog,O
‐,O
ical,O
details,O
about,O
index,O
and,O
reference,O
tests,O
.,O
We,O
categorised,O
the,O
tests,O
by,O
method,O
:,O
enzyme,O
linked,O
immunosorbent,O
assays,O
(,O
ELISAs,O
),O
.,O
lateral,O
flow,O
immunoassays,O
(,O
LFIAs,O
),O
.,O
or,O
chemiluminescent,O
immuno,O
as,O
‐,O
says,O
(,O
CLIAs,O
),O
.,O
In,O
several,O
studies,O
.,O
investigators,O
asses,O
sed,O
the,O
ac,O
‐,O
curacy,O
of,O
more,O
than,O
one,NUMBER
test,O
method,O
(,O
eg,O
.,O
ELISA,ORGANIZATION
and,O
LFIA,O
),O
or,O
more,O
than,O
one,NUMBER
particular,O
index,O
test,O
(,O
eg,O
.,O
one,NUMBER
study,O
evaluated,O
nine,NUMBER
dif,O
‐,O
ferent,O
LFIAs,O
),O
.,O
For,O
each,O
particular,O
index,O
test,O
performed,O
in,O
a,O
study,O
.,O
we,O
extracted,O
the,O
numbers,O
needed,O
to,O
construct,O
22,NUMBER
contingen,O
‐,O
cy,O
considered,O
its,O
own,O
study,O
arm,O
.,O
For,O
example,O
.,O
a,O
study,O
that,O
as,O
‐,O
sessed,O
nine,NUMBER
LFIAs,O
and,O
two,NUMBER
ELISAs,O
on,O
the,O
same,O
set,O
of,O
patients,O
would,O
contribute,O
11,NUMBER
study,O
arms,O
.,O
and,O
applicability,O
concerns,O
using,O
the,O
quality,O
assessment,O
of,O
diagnostic,O
accuracy,O
studies,O
2,NUMBER
(,O
QUADAS,O
‐,O
2,NUMBER
),O
tool,O
.,O
for,O
the,O
domains,O
of,O
patient,O
selection,O
.,O
perfor,O
‐,O
mance,O
of,O
the,O
index,O
test,O
.,O
performance,O
of,O
the,O
reference,O
test,O
.,O
and,O
flow,O
and,O
timing,O
(,O
for,O
risk,O
of,O
bias,O
only,O
),O
.11,NUMBER
Conflicts,O
were,O
re,O
‐,O
solved,O
through,O
consensus,O
.,O
We,O
performed,O
a,O
quality,O
assessment,O
for,O
each,O
test,O
method,O
and,O
population,O
.,O
For,O
ELISAs,O
on,O
the,O
same,O
set,O
of,O
patients,O
would,O
have,O
two,NUMBER
QUADAS,O
‐,O
2,NUMBER
assessments,O
(,O
one,NUMBER
for,O
the,O
LFIAs,O
and,O
one,NUMBER
for,O
the,O
ELISAs,O
),O
.,O
The,O
main,O
summary,O
measures,O
were,O
pooled,O
sensitivity,O
and,O
pooled,O
specificity,O
.,O
with,O
95,PERCENT
%,PERCENT
confidence,O
intervals,O
estimated,O
using,O
bivariate,O
generalised,O
linear,O
mixed,O
models,O
.,O
We,O
specified,O
random,O
effects,O
at,O
the,O
level,O
of,O
the,O
particular,O
study,O
and,O
of,O
the,O
particular,O
test,O
.,O
The,O
study,O
level,O
random,O
effect,O
accounted,O
for,O
correlation,O
of,O
results,O
that,O
could,O
arise,O
from,O
study,O
level,O
fac,O
‐,O
tors,O
.,O
such,O
as,O
using,O
the,O
same,O
set,O
of,O
samples,O
to,O
evaluate,O
more,O
than,O
one,NUMBER
test,O
in,O
a,O
study,O
.,O
The,O
test,O
level,O
random,O
effect,O
was,O
added,O
to,O
account,O
for,O
differences,O
arising,O
from,O
characteristics,O
of,O
individu,O
‐,O
al,O
tests,O
.,O
When,O
models,O
with,O
two,NUMBER
random,O
effects,O
did,O
not,O
converge,O
.,O
we,O
used,O
only,O
the,O
test,O
level,O
random,O
We,O
first,ORDINAL
estimated,O
pooled,O
sen,O
‐,O
sitivity,O
and,O
specificity,O
by,O
test,O
method,O
(,O
ELISA,LOCATION
.,O
LFIA,ORGANIZATION
.,O
CLIA,ORGANIZATION
),O
and,O
immunoglobulin,O
class,O
detected,O
(,O
IgM,O
or,O
IgG,O
.,O
or,O
both,O
),O
.,O
Separately,O
.,O
we,O
reported,O
results,O
from,O
studies,O
evaluating,O
serological,O
tests,O
that,O
measured,O
IgA,O
or,O
total,O
immunoglobulin,O
levels,O
and,O
without,O
meta,O
‐,O
analyses,O
owing,O
to,O
small,O
numbers,O
.,O
To,O
describe,O
heterogeneity,O
.,O
we,O
constructed,O
summary,O
receiver,O
operating,O
characteristic,O
(,O
ROC,COUNTRY
),O
curves,O
with,O
95,PERCENT
%,PERCENT
prediction,O
regions,O
.,O
estimated,O
using,O
bivariate,O
meta,O
‐,O
analysis,O
with,O
a,O
test,O
level,O
random,O
effect,O
only,O
.,O
and,O
forest,O
plots,O
.,O
As,O
our,O
models,O
were,O
bivariate,O
.,O
we,O
did,O
not,O
use,O
the,O
I2,O
statistic,O
.,O
Studies,O
that,O
did,O
not,O
report,O
both,O
sensitivity,O
and,O
specificity,O
were,O
excluded,O
from,O
bivariate,O
To,O
assess,O
prespecified,O
variables,O
as,O
potential,O
deter,O
minants,O
of,O
diagnostic,O
accuracy,O
.,O
we,O
compared,O
pooled,O
sensitivity,O
and,O
specificity,O
across,O
several,O
sub,O
‐,O
groups,O
the,O
level,O
of,O
patients,O
or,O
samples,O
;,O
the,O
type,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
or,O
an,O
in,O
‐,O
house,O
assay,O
;,O
whether,O
the,O
population,O
used,O
to,O
estimate,O
specificity,O
consisted,O
of,O
samples,O
collected,O
before,O
the,O
emergence,O
of,O
SARS,O
CoV,O
‐,O
2,NUMBER
.,O
individuals,O
without,O
suspected,O
covid,O
‐,O
19,NUMBER
tested,O
dur,O
‐,O
ing,O
the,O
epidemic,O
.,O
individuals,O
with,O
suspected,O
covid,O
‐,O
19,NUMBER
.,O
or,O
indi,O
‐,O
viduals,O
with,O
other,O
viral,O
infections,CAUSE_OF_DEATH
;,O
and,O
the,O
timing,O
of,O
sample,O
collection,O
in,O
relation,O
to,O
the,O
onset,O
of,O
symptoms,O
(,O
during,O
the,O
first,ORDINAL
week,DURATION
.,O
during,O
the,DATE
second,DATE
week,DATE
.,O
or,O
after,O
the,DATE
second,DATE
week,DATE
),O
.,O
In,O
these,O
analyses,O
.,O
to,O
maximize,O
sample,O
size,O
we,O
pooled,O
data,O
regardless,O
of,O
immunoglobulin,O
class,O
.,O
To,O
do,O
so,O
.,O
we,O
used,O
the,O
combined,O
IgG,O
and,O
IgM,O
result,O
when,O
available,O
.,O
otherwise,O
we,O
used,O
the,O
separate,O
IgG,O
and,O
IgM,O
same,O
test,O
level,O
and,O
study,O
level,O
random,O
effects,O
.,O
Because,O
data,O
were,O
not,O
available,O
to,O
study,O
the,O
association,O
between,O
the,O
timing,O
of,O
sam,O
‐,O
pling,O
and,O
specificity,O
.,O
this,O
analysis,O
was,O
Records,O
identied,O
through,O
database,O
searching,O
Records,O
aer,O
duplicates,O
removed,O
and,O
abstracts,O
screened,O
Records,O
excluded,O
Additional,O
records,O
identied,O
through,O
other,O
sources,O
Studies,O
not,O
reporting,O
accuracy,O
Reference,O
tests,O
ei,O
‐,O
ther,O
not,O
used,O
or,O
not,O
viral,O
culture,O
or,O
RT,O
‐,O
PCR,O
Other,O
diseases,CAUSE_OF_DEATH
not,O
covid,O
‐,O
19,NUMBER
Inadequate,O
results,O
report,O
Index,O
tests,O
not,O
relevant,O
Stud,O
‐,O
ies,O
included,O
(,O
73,NUMBER
arms,O
),O
Fig,O
1,NUMBER
|,O
Study,O
selection,O
.,O
RT,O
‐,O
PCR,O
=,O
reverse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
;,O
covid,O
‐,O
19,NUMBER
=,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
Geographical,O
location,O
:,O
United,COUNTRY
Kingdom,COUNTRY
United,COUNTRY
States,COUNTRY
Clinical,O
setting,O
:,O
Inpatient,O
only,O
Inpatient,O
and,O
outpatient,O
Not,O
re,O
‐,O
ported,O
Study,O
design,O
:,O
Time,O
from,O
symptom,O
onset,O
to,O
index,O
test,O
:,O
First,DATE
week,DATE
Second,DATE
week,DATE
Third,DATE
week,DATE
or,O
later,O
Accuracy,O
at,O
level,O
of,O
patient,O
or,O
sample,O
:,O
Population,O
for,O
estimating,O
specificity,O
:,O
Samples,O
collected,O
before,O
covid,O
‐,O
19,NUMBER
epidemic,O
Samples,O
collected,O
during,O
covid,O
‐,O
19,NUMBER
epidemic,O
in,O
individuals,O
not,O
suspected,O
of,O
having,O
covid,O
‐,O
19,NUMBER
Individuals,O
with,O
suspected,O
covid,O
‐,O
19,NUMBER
but,O
RT,O
‐,O
PCR,O
negative,O
result,O
Individuals,O
with,O
confirmed,O
other,O
viral,O
infection,CAUSE_OF_DEATH
**,O
Mix,O
of,O
above,O
No,O
of,O
No,O
of,O
No,O
of,O
No,O
of,O
No,O
of,O
No,O
of,O
No,O
of,O
No,O
of,O
ELISA,ORGANIZATION
=,O
enzyme,O
linked,O
immunosorbent,O
assay,O
;,O
LFIA,O
=,O
lateral,O
flow,O
immunoassay,O
;,O
CLIA,ORGANIZATION
=,O
chemiluminescent,O
immunoassay,O
;,O
RT,O
‐,O
PCR,O
=,O
reverse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
.,O
*,O
Includes,O
enzyme,O
immunoassay,O
.,O
fluo,O
‐,O
rescence,O
immunochromatographic,O
assay,O
.,O
liquid,O
phase,O
immunoassay,O
.,O
Cassaniti,O
et,O
al15,O
includes,O
two,NUMBER
distinct,O
populations,O
.,O
patients,O
who,O
were,O
triaged,O
or,O
admitted,O
to,O
hospital,O
.,O
with,O
different,O
study,O
design,O
(,O
cohort,O
and,O
case,O
‐,O
control,O
),O
.,O
This,O
study,O
as,O
two,NUMBER
different,O
cohorts,O
.,O
hence,O
sum,O
of,O
number,O
of,O
studies,O
across,O
LFIA,ORGANIZATION
rows,O
is,O
18,NUMBER
.,O
One,NUMBER
study,O
was,O
poorly,O
reported,O
.,O
and,O
it,O
was,O
difficult,O
to,O
classify,O
study,O
de,O
‐,O
sign,O
.,O
First,DATE
week,DATE
range,O
:,O
0,NUMBER
‐,O
7,DURATION
days,DURATION
(,O
one,NUMBER
cohort,O
with,O
0,NUMBER
‐,O
10,DURATION
days,DURATION
is,O
counted,O
in,O
this,O
group,O
),O
;,O
second,DATE
week,DATE
:,O
7,NUMBER
‐,O
14,DURATION
days,DURATION
;,O
third,DATE
week,DATE
:,O
15,NUMBER
days,DURATION
or,O
more,O
.,O
Patients,O
could,O
have,O
contributed,O
more,O
than,O
one,NUMBER
sam,O
‐,O
ple,O
.,O
and,O
analyses,O
did,O
not,O
account,O
for,O
correlation,O
.,O
Numbers,O
in,O
‐,O
clude,O
samples,O
and,O
patients,O
.,O
Some,O
studies,O
reported,O
more,O
than,O
one,NUMBER
type,O
of,O
population,O
to,O
access,O
specificity,O
.,O
Includes,O
studies,O
where,O
timing,O
was,O
unclear,O
.,O
**,O
Includes,O
some,O
samples,O
originating,O
from,O
be,O
‐,O
fore,O
the,O
covid,O
‐,O
19,NUMBER
epidemic,O
.,O
and,O
some,O
during,O
the,O
epidemic,O
.,O
as,O
fur,O
‐,O
ther,O
stratification,O
was,O
not,O
possible,O
.,O
done,O
with,O
univariate,O
mod,O
‐,O
els,O
and,O
included,O
studies,O
that,O
only,O
reported,O
sensitivity,O
.,O
We,O
used,O
the,O
statistical,O
software,O
R12,O
package,O
Lme413,O
for,O
meta,O
‐,O
analyses,O
.,O
and,O
package,O
mada,O
to,O
create,O
sum,O
mary,O
ROC,COUNTRY
curves,O
.14,NUMBER
Patient,O
and,O
public,O
involvement,O
Patients,O
were,O
not,O
involved,O
in,O
the,O
development,O
of,O
the,O
research,O
question,O
or,O
its,O
outcome,O
measures,O
.,O
conduct,O
of,O
records,O
(,O
4969,DATE
unique,O
),O
were,O
identified,O
through,O
data,O
searches,O
.,O
In,O
total,O
.,O
4696,DATE
records,O
based,O
on,O
screening,O
of,O
excluded,O
.,O
Forty,NUMBER
studies,O
totalling,O
73,NUMBER
study,O
arms15,O
‐,O
54,NUMBER
met,O
by,O
test,O
method,O
;,O
the,O
sum,O
of,O
the,O
number,O
of,O
studies,O
exceeds,O
40,NUMBER
because,O
some,O
evaluated,O
more,O
than,O
one,NUMBER
method,O
.,O
Seventy,NUMBER
per,O
cent,MONEY
(,O
28/40,NUMBER
),O
of,O
the,O
studies,O
were,O
from,O
Chi,PERSON
‐,PERSON
na,O
.16,O
‐,O
35,NUMBER
38,NUMBER
‐,O
41,NUMBER
45,NUMBER
‐,O
48,PERCENT
8,PERCENT
%,PERCENT
(,O
3/40,NUMBER
),O
from,O
Italy,COUNTRY
.15,O
36,NUMBER
43,NUMBER
and,O
the,O
re,O
‐,O
mainder,O
from,O
the,O
United,COUNTRY
States,COUNTRY
(,O
3/40,O
),O
.42,O
50,NUMBER
52,NUMBER
Denmark,COUNTRY
(,O
1/40,NUMBER
),O
.51,O
Spain,COUNTRY
(,O
1/40,NUMBER
),O
.37,O
Sweden,COUNTRY
(,O
1/40,NUMBER
),O
.53,O
Japan,COUNTRY
(,O
1/40,NUMBER
),O
.44,O
the,O
United,ORGANIZATION
King,ORGANIZATION
‐,O
dom,O
(,O
1/40,NUMBER
),O
.49,O
and,O
Germany,COUNTRY
(,O
1/40,NUMBER
),O
.54,NUMBER
Both,O
sensitivity,O
and,O
speci,O
‐,O
ficity,O
were,O
reported,O
in,O
80,PERCENT
%,PERCENT
(,O
32/40,NUMBER
),O
of,O
the,O
studies,O
.,O
sensitivity,O
alone,O
case,O
‐,O
control,O
design,O
for,O
selecting,O
the,O
study,O
population,O
and,O
10,PERCENT
%,PERCENT
(,O
4/40,NUMBER
),O
included,O
outpatient,O
populations,O
.,O
Disease,CAUSE_OF_DEATH
severity,O
was,O
reported,O
in,O
40,PERCENT
%,PERCENT
(,O
16/40,NUMBER
),O
and,O
sensitivity,O
stratified,O
by,O
time,O
since,O
symptom,O
onset,O
was,O
reported,O
in,O
45,PERCENT
%,PERCENT
(,O
18/40,NUMBER
),O
.,O
Several,O
studies,O
used,O
samples,O
rather,O
than,O
individual,O
patients,O
to,O
estimate,O
accuracy,O
.,O
In,O
these,O
studies,O
.,O
one,NUMBER
patient,O
could,O
have,O
contributed,O
multiple,O
sam,O
‐,O
ples,O
for,O
estimating,O
sensitivity,O
or,O
specificity,O
.,O
or,O
both,O
.,O
Ap,O
‐,O
proaches,O
to,O
estimating,O
specificity,O
included,O
using,O
specimens,O
col,O
‐,O
lected,O
before,O
the,O
emergence,O
of,O
covid,O
‐,O
19,NUMBER
;,O
specimens,O
collected,O
dur,O
‐,O
ing,O
the,O
epidemic,O
from,O
individuals,O
not,O
suspected,O
of,O
having,O
covid,O
‐,O
19,NUMBER
.,O
or,O
specimens,O
from,O
individuals,O
with,O
covid,O
‐,O
19,NUMBER
symptoms,O
and,O
a,O
negative,O
RT,O
‐,O
PCR,O
result,O
for,O
SARSCoV,O
‐,O
2,NUMBER
;,O
or,O
specimens,O
from,O
in,O
‐,O
dividuals,O
with,O
laboratory,O
confirmed,O
infection,CAUSE_OF_DEATH
with,O
other,O
viruses,O
(,O
respiratory,O
report,O
the,O
characteristics,O
of,O
each,O
individual,O
study,O
.,O
(,O
index,O
),O
and,O
reference,O
tests,O
that,O
were,O
used,O
in,O
the,O
details,O
for,O
each,O
study,O
.,O
Most,O
of,O
the,O
studies,O
evaluated,O
immunoglobulin,O
class,O
and,O
antigen,O
target,O
.,O
Among,O
17,NUMBER
studies,O
that,O
evaluated,O
potential,O
point,O
‐,O
of,O
‐,O
care,O
tests,O
(,O
LFIAs,O
),O
.,O
only,O
two,NUMBER
performed,O
testing,O
at,O
the,O
point,O
of,O
care,O
.,O
Direct,O
testing,O
on,O
whole,O
blood,O
specimensas,O
would,O
be,O
done,O
at,O
the,O
point,O
of,O
carewas,O
performed,O
in,O
6/17,O
(,O
35,PERCENT
%,PERCENT
),O
studies,O
of,O
LFIAs,O
.,O
and,O
outcomes,O
of,O
such,O
testing,O
Class,O
of,O
immunoglobulin,O
measured,O
by,O
index,O
test,O
:,O
IgM,O
and,O
IgG,O
Total,O
Ig,O
Antigen,O
target,O
of,O
immunoglobulin,O
measured,O
by,O
index,O
test,O
:,O
Surface,O
protein,O
Nucleocap,O
‐,O
sid,O
protein,O
Surface,O
and,O
nucleocapsid,O
proteins,O
Not,O
reported,O
Type,O
of,O
specimen,O
for,O
RT,O
‐,O
PCR,O
reference,O
test,O
:,O
Sputum,O
.,O
saliva,O
.,O
or,O
oral,O
.,O
throat,O
.,O
or,O
pharyngeal,O
Not,O
reported,O
No,O
of,O
specimens,O
for,O
RT,O
‐,O
PCR,O
reference,O
test,O
:,O
1,NUMBER
or,O
not,O
reported,O
RT,O
‐,O
PCR,O
=,O
reverse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
.,O
Denominator,O
is,O
39,NUMBER
studies,O
reporting,O
sensitivity,O
.,O
in,O
18,PERCENT
%,PERCENT
(,O
7/40,NUMBER
),O
.,O
and,O
specificity,O
alone,O
in,O
3,PERCENT
%,PERCENT
(,O
1/40,NUMBER
),O
.33,NUMBER
Risk,O
of,O
bias,O
Applicability,O
concerns,O
Fig,O
2,NUMBER
|,O
Summary,O
of,O
quality,O
assessment,O
of,O
diagnostic,O
accuracy,O
studies,O
2,NUMBER
(,O
QUADAS,O
‐,O
2,NUMBER
),O
assessment,O
Method,O
and,O
studies,O
ELISA,O
(,O
n,O
=,O
13,NUMBER
arms,O
),O
LFIA,O
(,O
n,O
=,O
36,NUMBER
arms,O
),O
Hospital,O
admission,O
group,O
Triage,O
group,O
CLIA,ORGANIZATION
(,O
n,O
=,O
10,NUMBER
arms,O
),O
IgG,O
or,O
IgM,O
Sensitivity,O
(,O
%,O
),O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Sensitivity,O
(,O
%,O
),O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Sensitivity,O
(,O
%,O
),O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Method,O
and,O
studies,O
Sensitivity,O
(,O
%,O
),O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
IgG,O
or,O
IgM,O
Sensitivity,O
(,O
%,O
),O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Sensitivity,O
(,O
%,O
),O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Ig,O
=,O
immunoglobu,O
‐,O
lin,O
;,O
TP,O
=,O
true,O
positive,O
;,O
FN,O
=,O
false,O
negative,O
;,O
TN,STATE_OR_PROVINCE
=,O
true,O
negative,O
;,O
FP,O
=,O
false,O
positive,O
;,O
ELISA,O
=,O
enzyme,O
linked,O
immunosorbent,O
assay,O
;,O
LFIA,ORGANIZATION
=,O
lateral,O
flow,O
immunoassay,O
;,O
CLIA,ORGANIZATION
=,O
chemiluminescent,O
immunoassay,O
.,O
*,O
Pooled,O
estimates,O
were,O
calculated,O
using,O
bivariate,O
random,O
effects,O
meta,O
‐,O
analysis,O
;,O
as,O
such,O
.,O
they,O
depart,O
from,O
what,O
would,O
be,O
estimated,O
by,O
simple,O
division,O
of,O
numerator,O
by,O
denominator,O
.,O
were,O
available,O
for,O
44,NUMBER
patients,O
across,O
all,O
study,O
arms,O
(,O
2,PERCENT
%,PERCENT
of,O
LFIAs,O
performed,O
),O
.,O
All,O
39,NUMBER
studies,O
that,O
reported,O
sensitivity,O
used,O
RT,O
‐,O
PCR,O
as,O
the,O
ref,O
‐,O
erence,O
standard,O
to,O
rule,O
in,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
but,O
the,O
type,O
and,O
number,O
of,O
specimens,O
varied,O
.,O
individual,O
QUADAS,O
‐,O
2,NUMBER
evaluations,O
.,O
For,O
the,O
patient,O
selection,O
domain,O
.,O
a,O
high,O
or,O
unclear,O
risk,O
of,O
bias,O
was,O
seen,O
in,O
98,PERCENT
%,PERCENT
(,O
48/49,NUMBER
),O
of,O
QUADAS,O
‐,O
2,NUMBER
assessments,O
.,O
mostly,O
related,O
to,O
a,O
case,O
‐,O
control,O
design,O
and,O
not,O
using,O
consecutive,O
or,O
random,O
sampling,O
.,O
For,O
the,O
index,O
test,O
domain,O
.,O
73,PERCENT
%,PERCENT
(,O
36/49,NUMBER
),O
of,O
assessments,O
concluded,O
a,O
high,O
or,O
unclear,O
risk,O
of,O
bias,O
because,O
it,O
was,O
not,O
clear,O
whether,O
the,O
serological,O
test,O
was,O
interpreted,O
blind,O
to,O
the,O
reference,O
standard,O
or,O
whether,O
the,O
cut,O
‐,O
off,O
values,O
for,O
classifying,O
results,O
as,O
posi,O
‐,O
tive,O
.,O
negative,O
.,O
or,O
indeterminate,O
were,O
prespecified,O
.,O
For,O
LFIAs,O
(,O
18,NUMBER
of,O
the,O
QUADAS,O
‐,O
2,NUMBER
assessments,O
),O
.,O
when,O
test,O
results,O
are,O
subjectively,O
interpreted,O
by,O
a,O
human,O
reader,TITLE
(,O
eg,O
.,O
appearance,O
of,O
a,O
line,O
),O
.,O
a,O
de,O
‐,O
scription,O
of,O
the,O
number,O
of,O
readers,O
and,O
assessment,O
of,O
reliability,O
were,O
provided,O
in,O
17,PERCENT
%,PERCENT
(,O
3/18,NUMBER
),O
of,O
assessments,O
.,O
For,O
the,O
reference,O
standard,O
domain,O
.,O
we,O
judged,O
the,O
risk,O
of,O
bias,O
as,O
unclear,O
in,O
94,PERCENT
%,PERCENT
(,O
46/49,NUMBER
),O
of,O
assessments,O
owing,O
to,O
inadequate,O
details,O
about,O
speci,O
‐,O
mens,O
used,O
for,O
RT,O
‐,O
PCR,O
or,O
use,O
of,O
specimens,O
other,O
than,O
nasopharyn,O
‐,O
geal,O
swabs,O
.,O
We,O
also,O
classified,O
the,O
risk,O
as,O
unclear,O
if,O
fewer,O
than,O
two,NUMBER
RT,O
‐,O
PCRs,O
were,O
used,O
to,O
rule,O
out,O
infection,CAUSE_OF_DEATH
.,O
or,O
if,O
the,O
number,O
was,O
not,O
reported,O
.,O
Risk,O
of,O
bias,O
from,O
flow,O
and,O
timing,O
was,O
high,O
or,O
un,O
‐,O
clear,O
in,O
67,PERCENT
%,PERCENT
(,O
33/49,NUMBER
),O
owing,O
to,O
missing,O
information,O
or,O
results,O
not,O
stratified,O
by,O
the,O
timing,O
of,O
sample,O
collection,O
in,O
relation,O
to,O
symptom,O
onset,O
.,O
Major,TITLE
applicability,O
concerns,O
for,O
the,O
index,O
test,O
were,O
seen,O
in,O
29,PERCENT
%,PERCENT
(,O
14/49,NUMBER
),O
of,O
assessments,O
.,O
mostly,O
owing,O
to,O
LFIA,O
be,O
‐,O
ing,O
performed,O
in,O
laboratories,O
and,O
not,O
using,O
point,O
‐,O
of,O
‐,O
care,O
type,O
sitivity,O
stratified,O
by,O
test,O
type,O
and,O
immunoglobulin,O
class,O
.,O
Within,O
each,O
test,O
method,O
(,O
CLIA,ORGANIZATION
.,O
ELISA,LOCATION
.,O
LFIA,O
),O
.,O
point,O
estimates,O
were,O
simi,O
‐,O
lar,O
between,O
the,O
different,O
types,O
of,O
immunoglobulins,O
.,O
and,O
confi,O
‐,O
dence,O
intervals,O
overlapped,O
.,O
Within,O
each,O
class,O
of,O
immunoglobulin,O
.,O
reports,O
on,O
specificity,O
.,O
Pooled,O
specificities,O
ranged,O
from,O
96.6,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
confidence,O
interval,O
94.3,PERCENT
%,PERCENT
to,O
98.2,PERCENT
%,PERCENT
),O
for,O
LFIAs,O
measuring,O
IgM,O
and,O
IgG,O
.,O
to,O
99.7,PERCENT
%,PERCENT
(,O
99.0,PERCENT
%,PERCENT
to,O
100,PERCENT
%,PERCENT
),O
for,O
ELISAs,O
measuring,O
IgM,O
.,O
Pooled,O
specificity,O
for,O
CLIA,ORGANIZATION
tests,O
that,O
measured,O
IgM,O
and,O
IgG,O
(,O
n,O
=,O
2,NUMBER
),O
could,O
not,O
be,O
estimated,O
because,O
of,O
non,O
‐,O
convergence,O
.,O
For,O
all,O
test,O
methods,O
and,O
immunoglobulin,O
classes,O
.,O
visual,O
inspection,O
of,O
summary,O
ROC,COUNTRY
curves,O
(,O
supplementary,O
showed,O
important,O
heterogeneity,O
.,O
speci,O
‐,O
ficity,O
reported,O
in,O
three,NUMBER
studies,O
that,O
used,O
sero,O
logical,O
test,O
methods,O
other,O
than,O
ELISAs,O
.,O
LFIAs,O
.,O
or,O
CLIAs,O
.,O
Sensitivity,O
or,O
speci,O
‐,O
ficity,O
.,O
or,O
both,O
were,O
low,O
for,O
all,O
.,O
with,O
the,O
exception,O
of,O
an,O
IgM,O
enzyme,O
immunoassay,O
reports,O
sensitivity,O
and,O
specificity,O
of,O
sero,O
‐,O
logical,O
tests,O
that,O
measured,O
IgA,O
(,O
one,NUMBER
ELISA,O
.,O
one,NUMBER
CLIA,ORGANIZATION
),O
47,NUMBER
51,NUMBER
and,O
those,O
measuring,O
total,O
immunoglobulin,O
levels,O
(,O
three,NUMBER
ELISAs,MISC
.,O
one,NUMBER
CLIA,ORGANIZATION
.,O
one,NUMBER
LFIA,O
),O
.20,NUMBER
30,NUMBER
51,NUMBER
All,O
four,NUMBER
studies,O
were,O
classified,O
as,O
high,O
risk,O
of,O
bias,O
from,O
patient,O
selection,O
.,O
and,O
unclear,O
risk,O
of,O
bias,O
from,O
performance,O
of,O
the,O
reference,O
standard,O
.,O
and,O
three,NUMBER
had,O
high,O
or,O
unclear,O
risk,O
of,O
bias,O
in,O
the,O
domains,O
of,O
index,O
test,O
performance,O
and,O
ranged,O
from,O
93.1,PERCENT
%,PERCENT
to,O
98.6,PERCENT
%,PERCENT
.,O
and,O
specificity,O
from,O
potential,O
sources,O
of,O
heterogeneity,O
in,O
sensitivity,O
accuracy,O
.,O
For,O
ELISAs,O
and,O
LFIAs,O
.,O
accuracy,O
estimates,O
at,O
the,O
sample,O
level,O
(,O
ie,O
.,O
in,O
studies,O
when,O
it,O
was,O
possible,O
for,O
patients,O
to,O
contribute,O
more,O
than,O
one,NUMBER
sample,O
to,O
the,O
analysis,O
),O
were,O
similar,O
to,O
estimates,O
using,O
only,O
one,NUMBER
sample,O
for,O
each,O
patient,O
.,O
For,O
CLIAs,O
.,O
specificity,O
was,O
higher,O
from,O
studies,O
reported,O
at,O
the,O
sample,O
level,O
.,O
Point,O
estimates,O
for,O
pooled,O
sensitivity,O
and,O
specificity,O
were,O
higher,O
when,O
both,O
surface,O
and,O
nu,O
‐,O
cleocapsid,O
proteins,O
were,O
used,O
.,O
although,O
confidence,O
intervals,O
overlapped,O
.,O
Point,O
estimates,O
of,O
pooled,O
sensitivity,O
were,O
all,O
three,NUMBER
methods,O
.,O
with,O
the,O
strongest,O
difference,O
seen,O
tests,O
was,O
88.2,PERCENT
%,PERCENT
(,O
83.6,PERCENT
%,PERCENT
to,O
91.3,PERCENT
%,PERCENT
),O
.,O
For,O
all,O
three,NUMBER
test,O
methods,O
.,O
pooled,O
specificity,O
was,O
high,O
when,O
measured,O
in,O
populations,O
where,O
covid,O
‐,O
19,NUMBER
was,O
not,O
sus,O
‐,O
pected,O
.,O
regardless,O
of,O
whether,O
the,O
sampling,O
had,O
been,O
done,O
before,O
or,O
during,O
the,O
epidemic,O
.,O
For,O
both,O
LFIAs,O
and,O
CLIAs,O
.,O
pooled,O
speci,O
‐,O
ficity,O
was,O
lower,O
among,O
individuals,O
with,O
suspected,O
covid,O
‐,O
19,NUMBER
com,O
‐,O
pared,O
with,O
other,O
groups,O
;,O
similar,O
data,O
were,O
not,O
available,O
for,O
ELISAs,O
.,O
For,O
LFIAs,O
.,O
Method,O
and,O
studies,O
ELISA,O
(,O
n,O
=,O
13,NUMBER
arms,O
),O
LFIA,O
(,O
n,O
=,O
36,NUMBER
arms,O
),O
Hospital,O
admission,O
group,O
Triage,O
group,O
CLIA,ORGANIZATION
(,O
n,O
=,O
10,NUMBER
arms,O
),O
IgG,O
or,O
IgM,O
Specificity,O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Specificity,O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Speci,O
‐,O
ficity,O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Method,O
and,O
studies,O
Specificity,O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
IgG,O
or,O
IgM,O
Specificity,O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Specificity,O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Not,O
estimable,O
Ig,O
=,O
immunoglobulin,O
;,O
TP,O
=,O
true,O
positive,O
;,O
FN,O
‐,O
false,O
negative,O
;,O
TN,STATE_OR_PROVINCE
=,O
true,O
negative,O
;,O
FP,O
=,O
false,O
positive,O
;,O
ELISA,O
=,O
enzyme,O
linked,O
immunosorbent,O
assay,O
;,O
LFIA,O
=,O
lateral,O
flow,O
immunoassay,O
;,O
CLIA,ORGANIZATION
=,O
chemiluminescent,O
im,O
‐,O
munoassay,O
.,O
*,O
Pooled,O
estimates,O
were,O
calculated,O
using,O
bivariate,O
random,O
effects,O
meta,O
‐,O
analysis,O
;,O
as,O
such,O
.,O
they,O
depart,O
from,O
what,O
would,O
be,O
estimated,O
by,O
simple,O
division,O
of,O
numerator,O
by,O
denomina,O
‐,O
tor,O
.,O
specificity,O
was,O
lower,O
when,O
estimated,O
in,O
individuals,O
with,O
other,O
viral,O
infections,CAUSE_OF_DEATH
.,O
but,O
this,O
was,O
not,O
the,O
case,O
for,O
ELISAs,O
or,O
CLIAs,O
.,O
timing,O
of,O
sample,O
collection,O
in,O
relation,O
to,O
symptom,O
onset,O
.,O
Regardless,O
of,O
immunoglobulin,O
class,O
or,O
test,O
method,O
.,O
pooled,O
sensi,O
‐,O
tivity,O
was,O
lowest,O
in,O
the,DURATION
first,DURATION
week,DURATION
of,O
symptom,O
onset,O
and,O
highest,O
in,O
the,DATE
third,DATE
week,DATE
or,O
later,O
.,O
Data,O
on,O
specificity,O
stratified,O
by,O
timing,O
were,O
not,O
with,O
examples,O
of,O
hypothetical,O
testing,O
outcomes,O
for,O
1000,DATE
people,O
undergoing,O
serological,O
testing,O
in,O
settings,O
with,O
a,O
prevalence,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
ranging,O
from,O
5,PERCENT
%,PERCENT
.,O
10,PERCENT
%,PERCENT
.,O
and,O
20,PERCENT
%,PERCENT
.,O
For,O
exam,O
‐,O
ple,O
.,O
in,O
a,O
population,O
with,O
a,O
true,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
prevalence,O
of,O
10,PERCENT
%,PERCENT
.,O
for,O
every,O
1000,NUMBER
people,O
tested,O
with,O
an,O
LFIA,O
:,O
among,O
those,O
who,O
had,O
covid,O
‐,O
19,NUMBER
.,O
66,NUMBER
will,O
test,O
positive,O
and,O
34,NUMBER
will,O
be,O
incorrectly,O
clas,O
‐,O
sified,O
as,O
uninfected,O
.,O
Among,O
those,O
without,O
covid,O
‐,O
19,NUMBER
.,O
869,NUMBER
will,O
test,O
negative,O
and,O
31,NUMBER
will,O
be,O
incorrectly,O
classified,O
as,O
having,O
antibod,O
‐,O
ies,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
evidence,O
on,O
the,O
diagnostic,O
accuracy,O
of,O
sero,O
‐,O
logical,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
was,O
found,O
to,O
be,O
characterised,O
by,O
high,O
risks,O
of,O
bias,O
.,O
heterogeneity,O
.,O
and,O
limited,O
generalisability,O
to,O
point,O
‐,O
of,O
‐,O
care,O
testing,O
and,O
to,O
outpatient,O
populations,O
.,O
We,O
found,O
sensitivities,O
were,O
consistently,O
lower,O
with,O
the,O
LFIA,O
method,O
com,O
‐,O
pared,O
with,O
ELISA,ORGANIZATION
and,O
CLIA,ORGANIZATION
methods,O
.,O
For,O
each,O
test,O
method,O
.,O
the,O
type,O
of,O
immunoglobulin,O
being,O
measuredIgM,O
.,O
IgG,O
.,O
or,O
bothwas,O
not,O
as,O
‐,O
sociated,O
with,O
diagnostic,O
accuracy,O
.,O
Pooled,O
sensitivities,O
were,O
low,O
‐,O
er,O
after,O
symptom,O
onset,O
compared,O
with,O
the,DATE
third,DATE
week,DATE
or,O
later,O
.,O
Pooled,O
specificities,O
of,O
each,O
test,O
method,O
were,O
high,O
.,O
However,O
.,O
stratified,O
results,O
suggested,O
specificity,O
was,O
lower,O
in,O
individuals,O
with,O
suspected,O
covid,O
‐,O
19,NUMBER
.,O
and,O
that,O
other,O
viral,O
infections,CAUSE_OF_DEATH
could,O
lead,O
to,O
false,O
positive,O
results,O
for,O
the,O
LFIA,O
method,O
.,O
These,O
obser,O
‐,O
vations,O
indicate,O
important,O
weaknesses,O
in,O
the,O
evidence,O
on,O
covid,O
‐,O
19,NUMBER
serological,O
tests,O
.,O
particularly,O
those,O
being,O
marketed,O
as,O
point,O
‐,O
of,O
‐,O
care,O
tests,O
.,O
Meaning,O
of,O
the,O
study,O
The,O
utility,O
of,O
a,O
low,O
cost,O
.,O
rapid,O
.,O
and,O
accurate,O
point,O
‐,O
ofcare,O
test55,O
has,O
spurred,O
the,O
develop,O
‐,O
ment,O
and,O
marketing,O
of,O
several,O
covid,O
‐,O
19,NUMBER
LFIA,O
serological,O
tests,O
.56,NUMBER
We,O
found,O
only,O
two,NUMBER
studies,O
where,O
LFIA,ORGANIZATION
had,O
been,O
performed,O
at,O
the,O
point,O
of,O
care,O
.,O
The,O
low,O
sensitivity,O
of,O
LFIA,O
is,O
of,O
particular,O
con,O
‐,O
cern,O
given,O
that,O
most,O
studies,O
used,O
sample,O
preparation,O
steps,O
that,O
are,O
likely,O
to,O
increase,O
sensitivity,O
compared,O
with,O
the,O
use,O
of,O
whole,O
blood,O
as,O
would,O
be,O
done,O
at,O
the,O
point,O
of,O
care,O
.,O
These,O
observations,O
argue,O
against,O
the,O
use,O
of,O
LFIA,O
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
be,O
‐,O
yond,O
research,O
and,O
evaluation,O
purposes,O
and,O
support,O
interim,O
recom,O
‐,O
mendations,O
issued,O
by,O
the,O
World,ORGANIZATION
Health,ORGANIZATION
Cautious,ORGANIZATION
interpretation,O
of,O
specificity,O
estimates,O
is,O
warranted,O
for,O
several,O
reasons,O
.,O
Impor,O
‐,O
tantly,O
.,O
few,O
data,O
were,O
available,O
from,O
people,O
who,O
were,O
tested,O
be,O
‐,O
cause,O
of,O
suspected,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
;,O
hence,O
our,O
overall,O
pooled,O
estimates,O
might,O
not,O
be,O
generalisable,O
to,O
people,O
who,O
need,O
testing,O
because,O
of,O
covid,O
‐,O
19,NUMBER
symptoms,O
.,O
For,O
CLIAs,O
.,O
the,O
lower,O
specificity,O
among,O
people,O
with,O
suspected,O
covid,O
‐,O
19,NUMBER
could,O
be,O
a,O
spurious,O
finding,O
from,O
a,O
false,O
negative,O
RT,O
‐,O
PCR,O
result,O
.,O
given,O
that,O
the,O
specificity,O
for,O
CLIAs,O
was,O
high,O
among,O
people,O
with,O
confirmed,O
other,O
viral,O
infec,O
‐,O
tions,O
.,O
By,O
contrast,O
.,O
for,O
LFIAs,O
.,O
other,O
viral,O
infections,CAUSE_OF_DEATH
could,O
have,O
contributed,O
to,O
the,O
lower,O
specificity,O
in,O
suspected,O
covid,O
‐,O
19,NUMBER
.,O
Our,O
time,O
stratified,O
analyses,O
suggest,O
that,O
current,DATE
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
have,O
limited,O
utility,O
in,O
the,O
diagnosis,O
of,O
acute,O
covid,O
‐,O
19,NUMBER
.,O
For,O
example,O
.,O
of,O
those,O
tested,O
for,O
covid,O
‐,O
19,NUMBER
within,O
one,NUMBER
week,DURATION
of,O
symptom,O
onset,O
.,O
on,O
average,O
44,PERCENT
%,PERCENT
to,O
87,PERCENT
%,PERCENT
will,O
be,O
falsely,O
identified,O
as,O
not,O
having,O
infection,CAUSE_OF_DEATH
.,O
And,O
while,O
sensitivity,O
esti,O
‐,O
mates,O
were,O
higher,O
in,O
the,DATE
third,DATE
week,DATE
or,O
later,O
.,O
even,O
at,O
this,O
time,O
point,O
we,O
found,O
important,O
false,O
negative,O
rates,O
.,O
For,O
example,O
.,O
in,O
people,O
with,O
covid,O
‐,O
19,NUMBER
who,O
are,O
tested,O
three,DURATION
weeks,DURATION
after,O
symptom,O
on,O
‐,O
set,O
.,O
ELISA,O
IgG,O
will,O
misclassify,O
18,PERCENT
%,PERCENT
as,O
not,O
having,O
been,O
infected,O
and,O
LFIA,O
IgG,O
will,O
Overall,O
.,O
the,O
poor,O
performance,O
of,O
existing,O
sero,O
‐,O
logical,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
raises,O
questions,O
about,O
the,O
utility,O
of,O
using,O
such,O
methods,O
for,O
medical,O
decision,O
making,O
.,O
particularly,O
giv,O
‐,O
en,O
time,O
and,O
effort,O
required,O
to,O
do,O
these,O
tests,O
and,O
the,O
challenging,O
workloads,O
many,O
clinics,O
are,O
facing,O
.,O
Our,O
findings,O
should,O
also,O
give,O
pause,O
to,O
governments,O
that,O
are,O
contemplating,O
the,O
use,O
of,O
serologi,O
‐,O
cal,O
testsin,O
particular,O
.,O
point,O
‐,O
of,O
‐,O
care,O
tests,O
to,O
issue,O
immunity,O
certificates,O
or,O
passports,O
.,O
For,O
example,O
.,O
if,O
an,O
LFIA,O
is,O
applied,O
to,O
a,O
population,O
with,O
a,O
true,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
prevalence,O
of,O
10,PERCENT
%,PERCENT
.,O
for,O
every,O
1000,NUMBER
people,O
tested,O
.,O
31,NUMBER
who,O
never,O
had,O
covid,O
‐,O
19,NUMBER
will,O
be,O
incorrectly,O
told,O
they,O
are,O
immune,O
.,O
and,O
34,NUMBER
people,O
who,O
Potential,O
source,O
of,O
het,O
‐,O
erogeneity,O
ELISA,O
:,O
Yes,O
ELISA,PERSON
:,O
No,O
LFIA,O
:,O
Yes,O
LFIA,O
:,O
No,O
CLIA,O
:,O
Yes,O
CLIA,ORGANIZATION
:,O
No,O
Data,O
level,O
:,O
ELISA,PERSON
:,O
Patient,O
ELISA,PERSON
:,O
Sample,O
LFIA,O
:,O
Patient,O
LFIA,O
:,O
Sample,O
CLIA,O
:,O
Patient,O
CLIA,O
:,O
Sample,O
Antigen,O
target,O
Surface,O
protein,O
Nucleocapsid,MISC
protein,O
Surface,O
and,O
nucleocapsid,O
proteins,O
Surface,O
protein,O
Nucleocapsid,MISC
protein,O
Surface,O
and,O
nucleocapsid,O
proteins,O
Surface,O
protein,O
Nucleocapsid,MISC
protein,O
Surface,O
and,O
nucleo,O
‐,O
capsid,O
proteins,O
ELISA,PERSON
:,O
Yes,O
ELISA,PERSON
:,O
No,O
LFIA,O
:,O
Yes,O
LFIA,O
:,O
No,O
CLIA,O
:,O
Yes,O
CLIA,ORGANIZATION
:,O
No,O
Population,O
for,O
estimating,O
specificity,O
Samples,O
collected,O
before,O
covid,O
‐,O
19,NUMBER
epidemic,O
Samples,O
collected,O
during,O
covid,O
‐,O
19,NUMBER
epi,O
‐,O
demic,O
in,O
individuals,O
not,O
suspected,O
of,O
having,O
covid,O
‐,O
19,NUMBER
Individuals,O
with,O
suspected,O
covid,O
‐,O
19,NUMBER
but,O
RT,O
‐,O
PCR,O
negative,O
result,O
Individuals,O
with,O
confirmed,O
other,O
viral,O
infection,CAUSE_OF_DEATH
Samples,O
collected,O
before,O
covid,O
‐,O
19,NUMBER
epidemic,O
Samples,O
collected,O
during,O
covid,O
‐,O
19,NUMBER
epidemic,O
in,O
individuals,O
not,O
suspected,O
of,O
having,O
covid,O
‐,O
19,NUMBER
Individuals,O
with,O
suspected,O
covid,O
‐,O
19,NUMBER
but,O
RT,O
‐,O
PCR,O
negative,O
result,O
Individuals,O
with,O
confirmed,O
other,O
viral,O
infection,CAUSE_OF_DEATH
Samples,O
collected,O
before,O
covid,O
‐,O
19,NUMBER
epidemic,O
Samples,O
collected,O
during,O
covid,O
‐,O
19,NUMBER
epidemic,O
in,O
individu,O
‐,O
als,O
not,O
suspected,O
of,O
having,O
covid,O
‐,O
19,NUMBER
Individuals,O
with,O
suspected,O
covid,O
‐,O
19,NUMBER
but,O
RT,O
‐,O
PCR,O
negative,O
result,O
Individuals,O
with,O
confirmed,O
other,O
viral,O
infection,CAUSE_OF_DEATH
No,MISC
of,MISC
Pooled,MISC
sensitivity,O
Pooled,O
specificity,O
TP,O
=,O
true,O
positive,O
;,O
FN,O
=,O
false,O
negative,O
;,O
TN,STATE_OR_PROVINCE
=,O
true,O
negative,O
;,O
FP,O
=,O
false,O
positive,O
;,O
ELISA,O
=,O
enzyme,O
linked,O
immunosorbent,O
assay,O
;,O
LFIA,O
=,O
lateral,O
flow,O
immunoassay,O
;,O
CLIA,ORGANIZATION
=,O
chemiluminescent,O
immunoassay,O
;,O
RT,O
‐,O
PCR,O
=,O
re,O
‐,O
verse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
*,O
Pooled,O
estimates,O
were,O
calculated,O
using,O
bivariate,O
random,O
effects,O
meta,O
‐,O
analysis,O
;,O
as,O
such,O
.,O
they,O
depart,O
from,O
what,O
would,O
be,O
estimated,O
by,O
simple,O
division,O
of,O
numerator,O
by,O
denominator,O
.,O
Pooled,O
estimates,O
were,O
calculated,O
using,O
univariate,O
random,O
effects,O
meta,O
‐,O
analysis,O
.,O
had,O
covid,O
‐,O
19,NUMBER
will,O
be,O
incorrectly,O
told,O
that,O
they,O
were,O
never,O
infected,O
.,O
have,O
taken,O
an,O
unprecedented,O
larger,O
role58,O
in,O
discussions,O
and,O
policy,O
making,O
around,O
covid,O
‐,O
19hence,O
the,O
impor,O
Time,O
post,O
‐,O
onset,O
First,DATE
week,DATE
Second,ORDINAL
week,DATE
Third,DATE
week,DATE
or,DATE
later,DATE
First,DATE
week,DATE
Second,DATE
week,DATE
Third,DATE
week,DATE
or,O
later,DATE
First,DATE
week,DATE
Second,DATE
week,DATE
Third,DATE
week,DATE
or,O
later,O
No,O
of,O
arms,O
Pooled,O
sensitivity,O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
No,O
of,O
arms,O
Pooled,O
sensitivity,O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Ig,O
=,O
immunoglobulin,O
;,O
TP,O
=,O
true,O
positive,O
;,O
FN,O
=,O
false,O
negative,O
;,O
ELISA,O
=,O
enzyme,O
linked,O
immunosorbent,O
assay,O
;,O
LFIA,O
=,O
lateral,O
flow,O
im,O
‐,O
munoassay,O
;,O
CLIA,ORGANIZATION
=,O
chemiluminescent,O
immunoassay,O
.,O
*,O
First,DATE
week,DATE
range,O
:,O
0,NUMBER
‐,O
7,DURATION
days,DURATION
(,O
one,NUMBER
cohort,O
reporting,O
0,NUMBER
‐,O
10,DURATION
days,DURATION
is,O
counted,O
here,O
),O
.,O
second,ORDINAL
week,DURATION
:,O
7,NUMBER
‐,O
14,DATE
days,DATE
.,DATE
third,DATE
week,DATE
:,O
15,DURATION
days,DURATION
or,O
more,O
.,O
Pooled,O
estimates,O
were,O
calculated,O
using,O
univariate,O
random,O
effects,O
meta,O
‐,O
analysis,O
.,O
which,O
is,O
why,O
they,O
depart,O
from,O
estimates,O
calculated,O
by,O
simple,O
di,O
‐,O
vision,O
of,O
true,O
positives,O
by,O
the,O
sum,O
of,O
true,O
positives,O
and,O
false,O
negatives,O
.,O
potential,O
sources,O
of,O
bias,O
.,O
Finally,O
.,O
a,DURATION
second,DURATION
investi,O
‐,O
gator,O
verified,O
all,O
data,O
extraction,O
.,O
Our,O
study,O
also,O
has,O
some,O
lim,O
‐,O
itations,O
.,O
Most,O
impor,O
tantly,O
.,O
we,O
compared,O
pooled,O
estimates,O
between,O
diffe,O
rent,O
study,O
populations,O
.,O
As,O
such,O
.,O
the,O
possibility,O
of,O
con,O
‐,O
founding,O
exists,O
(,O
eg,O
.,O
from,O
differences,O
in,O
timing,O
of,O
sampling,O
be,O
‐,O
tween,O
studies,O
),O
.,O
explaining,O
differences,O
in,O
sensitivity,O
or,O
speci,O
‐,O
ficity,O
.59,NUMBER
This,O
approach,O
was,O
taken,O
because,O
few,O
studies,O
performed,O
head,O
‐,O
to,O
‐,O
head,O
comparisons,O
.,O
We,O
did,O
not,O
perform,O
metaregression,O
as,O
many,O
studies,O
would,O
have,O
been,O
excluded,O
owing,O
to,O
limited,O
reporting,O
of,O
covariates,O
.,O
Another,O
limitation,O
is,O
that,O
as,O
we,O
did,O
not,O
search,O
Embase,O
we,O
might,O
have,O
Conclusion,O
and,O
future,DATE
research,O
Future,DATE
stud,O
‐,O
ies,O
to,O
evaluate,O
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
should,O
be,O
designed,O
to,O
overcome,O
the,O
major,O
limitations,O
of,O
the,O
existing,O
evidence,O
base,O
.,O
This,O
can,O
be,O
readily,O
accomplished,O
by,O
adhering,O
to,O
the,O
fundamentals,O
of,O
the,O
design,O
for,O
diagnostic,O
accuracy,O
studies,O
:,O
a,O
well,O
defined,O
use,O
‐,O
case,O
(,O
ie,O
.,O
specific,O
purpose,O
for,O
which,O
the,O
test,O
is,O
being,O
used,O
),O
;,O
consecutive,O
sampling,O
of,O
the,O
target,O
population,O
within,O
the,O
target,O
use,O
‐,O
case,O
;,O
performance,O
of,O
the,O
index,O
test,O
in,O
a,O
standardised,O
and,O
blinded,O
manner,O
using,O
the,O
same,O
methods,O
that,O
will,O
be,O
applied,O
in,O
the,O
specialty,O
;,O
and,O
ensuring,O
the,O
reference,O
test,O
is,O
accurate,O
.,O
performed,O
on,O
all,O
participants,O
.,O
and,O
interpreted,O
blind,O
to,O
the,O
results,O
of,O
the,O
index,O
test,O
.,O
To,O
reduce,O
the,O
likeli,O
Results,O
per,O
1000,DATE
patients,O
tested,O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
Test,O
method,O
Population,O
:,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infected,O
ELISA,O
(,O
IgG,O
or,O
IgM,O
),O
:,O
9,NUMBER
studies,O
.,O
766,NUMBER
samples,O
.,O
Pooled,O
sensitivity,O
84.3,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
75.6,PERCENT
%,PERCENT
to,O
90.9,PERCENT
%,PERCENT
),O
LFIA,O
(,O
IgG,O
or,O
IgM,O
),O
:,O
11,NUMBER
studies,O
.,O
2660,DATE
samples,O
.,O
Pooled,O
sensitivity,O
66.0,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
49.3,PERCENT
%,PERCENT
to,O
79.3,PERCENT
%,PERCENT
),O
CLIA,ORGANIZATION
(,O
IgG,O
or,O
IgM,O
),O
:,O
2,NUMBER
studies,O
.,O
375,NUMBER
samples,O
.,O
Pooled,O
sensitivity,O
97.8,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
46.2,PERCENT
%,PERCENT
to,O
100,PERCENT
%,PERCENT
),O
Population,O
:,O
not,O
infected,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
ELISA,ORGANIZATION
(,O
IgG,O
or,O
IgM,O
),O
:,O
6,NUMBER
studies,O
.,O
1109,DATE
samples,O
.,O
Pooled,O
specificity,O
97.6,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
93.2,PERCENT
%,PERCENT
to,O
99.4,PERCENT
%,PERCENT
),O
LFIA,O
(,O
IgG,O
or,O
IgM,O
),O
:,O
11,NUMBER
studies,O
.,O
2874,DATE
sam,O
‐,O
ples,O
.,O
Pooled,O
specificity,O
96.6,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
94.3,PERCENT
%,PERCENT
to,O
98.2,PERCENT
%,PERCENT
),O
9,NUMBER
studies,O
.,O
2804,NUMBER
samples,O
.,O
Pooled,O
specificity,O
97.8,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
62.9,PERCENT
%,PERCENT
to,O
99.9,PERCENT
%,PERCENT
),O
Classification,O
by,O
serology,O
test,O
Correctly,O
classified,O
as,O
infected,O
Incorrectly,O
classified,O
as,O
uninfected,O
Correctly,O
classified,O
as,O
in,O
‐,O
fected,O
Incorrectly,O
classified,O
as,O
uninfected,O
Correctly,O
classified,O
as,O
infected,O
Incorrectly,O
classified,O
as,O
uninfected,O
Correctly,O
clas,O
‐,O
sified,O
as,O
uninfected,O
Incorrectly,O
classified,O
as,O
infected,O
Correctly,O
classified,O
as,O
uninfected,O
Incorrectly,O
classified,O
as,O
infected,O
Cor,O
‐,O
rectly,O
classified,O
as,O
uninfected,O
Incorrectly,O
classified,O
as,O
infect,O
‐,O
ed,O
Quality,O
of,O
evidence,O
and,O
practical,O
implications,O
:,O
Pooled,O
sensi,O
‐,O
tivity,O
and,O
specificity,O
should,O
be,O
interpreted,O
with,O
caution,O
.,O
Accu,O
‐,O
racy,O
might,O
have,O
been,O
over,O
‐,O
estimated,O
in,O
most,O
studies,O
owing,O
to,O
bias,O
arising,O
from,O
patient,O
selection,O
or,O
how,O
index,O
and,O
reference,O
tests,O
were,O
performed,O
.,O
or,O
both,O
.,O
Estimates,O
of,O
sensitivity,O
and,O
specificity,O
were,O
inconsistent,O
between,O
studies,O
(,O
heterogeneity,O
was,O
important,O
),O
.,O
Estimates,O
might,O
have,O
limited,O
applicability,O
to,O
outpatient,O
settings,O
and,O
for,O
testing,O
at,O
the,O
point,O
of,O
care,O
.,O
Point,O
‐,O
of,O
‐,O
care,O
LFIAs,O
consis,O
‐,O
tently,O
had,O
the,O
lowest,O
sensitivity,O
and,O
specificity,O
.,O
The,O
poorest,O
RT,O
‐,O
PCR,O
=,O
reverse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
;,O
ELISA,O
=,O
en,O
‐,O
zyme,O
linked,O
immunosorbent,O
assay,O
;,O
LFIA,O
=,O
lateral,O
flow,O
immunoassay,O
;,O
CLIA,ORGANIZATION
=,O
chemiluminescent,O
immunoassay,O
;,O
Ig,O
=,O
immunoglobulin,O
;,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
=,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
;,O
covid,O
‐,O
19,NUMBER
=,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
.,O
Index,O
test,O
:,O
serology,O
tests,O
to,O
detect,O
immunoglobulins,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Target,O
condition,O
:,O
covid,O
‐,O
19,NUMBER
.,O
reference,O
standard,O
:,O
RT,O
‐,O
PCR,O
.,O
Studies,O
:,O
predominantly,O
case,O
‐,O
control,O
design,O
diagnostic,O
test,O
accuracy,O
.,O
hood,O
of,O
misclassification,O
.,O
the,O
reference,O
standard,O
should,O
consist,O
of,O
RT,O
‐,O
PCR,O
performed,O
on,O
at,O
least,O
two,NUMBER
consecutive,O
specimens,O
.,O
and,O
.,O
when,O
feasible,O
.,O
include,O
viral,O
cul,O
‐,O
tures,O
.,O
To,O
reduce,O
variability,O
in,O
estimates,O
and,O
enhance,O
generalis,O
‐,O
ability,O
.,O
sensitivity,O
and,O
specificity,O
should,O
be,O
stratified,O
by,O
set,O
‐,O
ting,O
(,O
outpatient,O
versus,O
inpatient,O
),O
.,O
severity,O
of,O
illness,CAUSE_OF_DEATH
.,O
and,O
the,O
number,O
of,O
days,DURATION
elapsed,O
since,O
symptom,O
onset,O
.,O
In,O
summary,O
.,O
we,O
have,O
found,O
major,O
weaknesses,O
in,O
the,O
evidence,O
base,O
for,O
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
.,O
The,O
evidence,O
does,O
not,O
support,O
the,O
continued,O
use,O
of,O
existing,O
point,O
‐,O
of,O
‐,O
care,O
serological,O
tests,O
for,O
covid,O
‐,O
19,NUMBER
.,O
While,O
the,O
scientific,O
community,O
should,O
be,O
lauded,O
for,O
the,O
pace,O
at,O
which,O
novel,O
serological,O
tests,O
have,O
been,O
developed,O
.,O
this,O
studies,O
to,O
evaluate,O
these,O
tools,O
.,O
With,O
international,O
collaboration,O
.,O
such,O
studies,O
could,O
be,O
rapidly,O
conducted,O
and,O
provide,O
less,O
biased,O
.,O
more,O
precise,O
.,O
and,O
more,O
generalisable,O
information,O
on,O
which,O
to,O
base,O
clinical,O
and,O
pub,O
‐,O
lic,O
health,O
policy,O
to,O
alleviate,O
the,O
unprecedented,O
global,O
health,O
emergency,O
that,O
is,O
covid,O
‐,O
19,NUMBER
.,O
assistance,O
in,O
developing,O
the,O
search,O
strategy,O
for,O
Ovid,LOCATION
‐,O
Medline,ORGANIZATION
and,O
the,O
preprint,O
literature,O
.,O
and,O
Coralie,PERSON
Gesic,PERSON
for,O
designing,O
the,O
forest,O
plots,O
.,O
The,O
Contributors,O
:,O
MLB,ORGANIZATION
and,O
FAK,O
(,O
equally,O
),O
and,O
AB,STATE_OR_PROVINCE
.,O
DM,O
.,O
and,O
JC,ORGANIZATION
conceived,O
the,O
study,O
and,O
study,O
design,O
.,O
MLB,ORGANIZATION
drafted,O
the,O
initial,O
search,O
strategy,O
and,O
execut,O
‐,O
ed,O
the,O
search,O
.,O
MLB,ORGANIZATION
.,O
GT,O
.,O
and,O
FAK,O
screened,O
the,O
studies,O
.,O
MLB,ORGANIZATION
.,O
GT,O
.,O
SL,O
.,O
EM,O
.,O
AT,O
.,O
ZL,O
.,O
and,O
SA,ORGANIZATION
extracted,O
data,O
extraction,O
and,O
performed,O
the,O
quality,O
assessment,O
.,O
MLB,ORGANIZATION
.,O
AB,ORGANIZATION
.,O
FAK,O
.,O
and,O
ZL,O
analysed,O
the,O
data,O
.,O
MLB,ORGANIZATION
criteria,O
have,O
been,O
omitted,O
.,O
Funding,O
:,O
This,O
study,O
was,O
funded,O
(,O
publication,O
costs,O
),O
by,O
a,O
grant,O
(,O
ECRF,O
‐,O
R1,O
‐,O
30,NUMBER
),O
from,O
the,O
McGill,O
In,O
‐,O
terdisciplinary,O
Initiative,O
in,O
Infection,ORGANIZATION
Health,ORGANIZATION
Research,ORGANIZATION
(,O
award,O
#FRD143350,O
),O
.,O
JRC,O
is,O
supported,O
by,O
Fonds,ORGANIZATION
de,ORGANIZATION
Recherche,ORGANIZATION
Sante,ORGANIZATION
Quebec,ORGANIZATION
(,O
FRSQ,O
award,O
#,MONEY
258907,MONEY
and,O
#,MONEY
287869,MONEY
),O
.,O
SL,O
holds,O
a,O
research,O
training,O
award,O
from,O
the,O
FRSQ,O
.,O
AB,ORGANIZATION
holds,O
a,O
research,O
salary,O
award,O
from,O
the,O
FRSQ,O
.,O
AT,O
is,O
supported,O
by,O
Conselho,ORGANIZATION
Nacional,ORGANIZATION
de,ORGANIZATION
Ensino,ORGANIZATION
.,O
Pesquisa,PERSON
e,O
Desenvolvimento,PERSON
Tecnolgico,PERSON
(,O
award,O
#,MONEY
303267,MONEY
/,O
2018,DATE
‐,O
6,NUMBER
),O
.,O
FAK,O
receives,O
salary,O
support,O
from,O
the,O
had,O
no,O
input,O
into,O
the,O
study,O
design,O
.,O
data,O
collection,O
.,O
data,O
analysis,O
or,O
interpretation,O
.,O
report,O
writing,O
.,O
or,O
the,O
decision,O
to,O
submit,O
the,O
paper,O
for,O
disclosure.pdf,O
and,O
declare,O
:,O
SL,O
reports,O
personal,O
fees,O
from,O
Carebook,ORGANIZATION
Technologies,ORGANIZATION
.,O
outside,O
the,O
submitted,O
work,O
;,O
no,O
financial,O
relationships,O
with,O
any,O
organisations,O
that,O
might,O
have,O
an,O
interest,O
in,O
the,O
submitted,O
work,O
in,O
the,O
previous,O
three,DURATION
years,DURATION
;,O
no,O
other,O
relationships,O
or,O
activities,O
that,O
could,O
ap,O
‐,O
pear,O
to,O
have,O
influenced,O
the,O
submitted,O
work,O
.,O
Ethical,O
approval,O
:,O
Not,O
required,O
.,O
accurate,O
.,O
and,O
transparent,O
account,O
of,O
the,O
study,O
be,O
‐,O
ing,O
reported,O
;,O
that,O
no,O
important,O
aspects,O
of,O
the,O
study,O
have,O
been,O
omitted,O
;,O
and,O
that,O
any,O
discrepancies,O
from,O
the,O
study,O
as,O
planned,O
(,O
and,O
.,O
if,O
relevant,O
.,O
registered,O
),O
have,O
been,O
explained,O
.,O
Dissemina,O
‐,O
tion,O
to,O
participants,O
and,O
related,O
patient,O
and,O
public,O
communities,O
:,O
The,O
results,O
of,O
the,O
meta,O
‐,O
analysis,O
will,O
be,O
disseminated,O
to,O
pa,O
‐,O
tients,O
.,O
providers,O
.,O
policy,O
makers,O
through,O
social,O
media,O
.,O
and,O
aca,O
‐,O
demic,O
and,O
institutional,O
networks,O
.,O
which,O
permits,O
others,O
to,O
dis,O
‐,O
tribute,O
.,O
remix,O
.,O
adapt,O
.,O
build,O
upon,O
this,O
work,O
Winichakoon,O
P,O
.,O
Chai,PERSON
‐,PERSON
warith,O
R,O
.,O
Liwsrisakun,PERSON
C,PERSON
.,O
et,O
al,O
.,O
Negative,O
nasopharyngeal,O
and,O
oropharyngeal,O
swabs,O
do,O
not,O
rule,O
out,O
covid,O
‐,O
19,NUMBER
.,O
J,PERSON
Chen,PERSON
Z,PERSON
.,O
Li,PERSON
Y,PERSON
.,O
Wu,PERSON
B,O
.,O
Hou,PERSON
Y,PERSON
.,O
Bao,PERSON
J,PERSON
.,O
Deng,PERSON
X,PERSON
.,O
A,O
patient,O
with,O
covid,O
‐,O
19,NUMBER
presenting,O
a,O
false,O
‐,O
negative,O
reverse,O
transcriptase,O
polymerase,O
chain,O
Sethuraman,PERSON
N,O
.,O
Jeremiah,PERSON
SS,PERSON
.,O
Ryo,PERSON
A.,O
Interpreting,O
Diagnostic,O
Tests,O
for,O
American,NATIONALITY
Society,ORGANIZATION
for,ORGANIZATION
Microbiology,ORGANIZATION
.,O
ASM,ORGANIZATION
expresses,O
concern,O
about,O
Maxmen,PERSON
A.,PERSON
The,O
researchers,O
taking,O
a,O
gamble,O
with,O
antibody,O
tests,O
for,O
Liberati,PERSON
A,O
.,O
Altman,PERSON
DG,PERSON
.,O
Tetzlaff,PERSON
J,PERSON
.,O
et,O
al,O
.,O
The,O
PRISMA,ORGANIZATION
statement,O
for,O
evalu,O
‐,O
ate,O
healthcare,O
interventions,O
:,O
explanation,O
and,O
elaboration,O
.,O
Saah,O
AJ,O
.,O
Hoover,PERSON
DR.,O
Sensitivity,O
and,O
specificity,O
reconsidered,O
:,O
the,O
meaning,O
of,O
these,O
terms,O
in,O
analytical,O
and,O
diagnostic,O
settings,O
.,O
Meyer,PERSON
B,O
.,O
Drosten,PERSON
C,O
.,O
Mller,PERSON
MA,PERSON
.,O
Serological,O
assays,O
for,O
emerging,O
coronaviruses,O
:,O
challenges,O
and,O
pitfalls,O
.,O
Virus,O
Res,O
2014,DATE
;,O
194:175,NUMBER
‐,O
83,NUMBER
.,O
Woo,O
PC,O
.,O
Lau,PERSON
SK,STATE_OR_PROVINCE
.,O
Wong,ORGANIZATION
BH,ORGANIZATION
.,O
et,O
al,O
.,O
Differential,O
sensitivities,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
coron,O
‐,O
avirus,O
spike,O
polypeptide,O
enzyme,O
‐,O
linked,O
immunosorbent,O
assay,O
(,O
ELISA,ORGANIZATION
),O
and,O
SARS,O
coronavirus,O
nucleocapsid,O
protein,O
ELISA,O
for,O
sero,O
‐,O
diagnosis,O
of,O
SARS,O
coronavirus,O
Woo,O
PCY,O
.,O
Lau,PERSON
SKP,O
.,O
Wong,ORGANIZATION
BHL,ORGANIZATION
.,O
et,O
al,O
.,O
Detection,O
of,O
specific,O
antibodies,O
to,O
severe,O
acute,O
respiratory,O
syn,O
‐,O
drome,O
(,O
SARS,O
),O
coronavirus,O
nucleocapsid,O
protein,O
for,O
serodiagnosis,O
of,O
SARS,O
coronavirus,O
Whiting,O
PF,O
.,O
Rutjes,O
AW,O
.,O
Westwood,O
ME,STATE_OR_PROVINCE
.,O
et,O
al,O
.,O
QUADAS,O
‐,O
2,NUMBER
Group,O
.,O
QUADAS,O
‐,O
2,NUMBER
:,O
a,O
revised,O
tool,O
for,O
the,O
quality,O
assess,O
‐,O
ment,O
of,O
diagnostic,O
accuracy,O
studies,O
.,O
Ann,PERSON
Intern,PERSON
Med,PERSON
2011,DATE
;,O
155:529,NUMBER
‐,O
36,NUMBER
.,O
R,O
:,O
A,O
language,O
and,O
environment,O
for,O
statistical,O
computing,O
[,O
program,O
],O
:,O
Bates,PERSON
D,O
.,O
Mchler,PERSON
M,O
.,O
Bolker,PERSON
B,PERSON
.,O
et,O
al,O
.,O
Fitting,O
linear,O
mixed,O
‐,O
effects,O
Cassaniti,MISC
I,O
.,O
Novazzi,O
F,O
.,O
Giardina,PERSON
F,O
.,O
et,O
al,O
.,O
Members,O
of,O
the,O
San,O
Matteo,O
Pavia,O
COVID,O
‐,O
19,NUMBER
Task,O
Force,O
.,O
Performance,O
of,O
VivaDiag,O
COVID,O
‐,O
19,NUMBER
IgM,O
/,O
IgG,O
Rapid,O
Test,O
is,O
inadequate,O
for,O
diagno,O
‐,O
sis,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
acute,O
patients,O
referring,O
to,O
emergency,O
room,O
de,O
‐,O
partment,O
.,O
J,PERSON
Med,PERSON
Gao,PERSON
HX,PERSON
.,O
Li,PERSON
YN,O
.,O
Xu,PERSON
ZG,PERSON
.,O
et,O
al,O
.,O
Detection,O
of,O
serum,O
immunoglobulin,O
M,O
and,O
immunoglobulin,O
G,O
antibodies,O
in,O
2019,DATE
novel,O
coronavirus,O
infected,O
patients,O
from,O
different,O
stages,O
.,O
Guo,PERSON
L,PERSON
.,O
Ren,PERSON
L,O
.,O
Yang,PERSON
S,PERSON
.,O
et,O
al,O
.,O
Profiling,O
early,O
humoral,O
response,O
to,O
diagnose,O
novel,O
coronavirus,O
disease,CAUSE_OF_DEATH
(,O
covid,O
‐,O
19,NUMBER
),O
.,O
Clin,O
Infect,O
Liu,PERSON
W,PERSON
.,O
Liu,PERSON
L,PERSON
.,O
Kou,PERSON
G,PERSON
.,O
et,O
al,O
.,O
Evaluation,O
of,O
nucleocapsid,O
and,O
spike,O
protein,O
‐,O
based,O
ELISAs,O
for,O
detecting,O
antibodies,O
against,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
J,PERSON
Zhang,PERSON
W,PERSON
.,O
Du,PERSON
RH,O
.,O
Li,PERSON
B,PERSON
.,O
et,O
al,O
.,O
Molecular,O
and,O
serological,O
investigation,O
of,O
2019,DATE
‐,O
nCoV,O
infected,O
patients,O
:,O
implication,O
of,O
multiple,O
shedding,O
Zhao,PERSON
J,PERSON
.,O
Yuan,O
Q,O
.,O
Wang,PERSON
H,PERSON
.,O
et,O
al,O
.,O
Antibody,O
responses,O
to,O
SARSCoV,O
‐,O
2,NUMBER
in,O
patients,O
of,O
novel,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
.,O
Clin,O
Infect,O
To,O
KK,O
.,O
Tsang,PERSON
OT,O
.,O
Leung,PERSON
WS,PERSON
.,O
et,O
al,O
.,O
Temporal,O
profiles,O
of,O
viral,O
load,O
in,O
posterior,O
oropharyngeal,O
saliva,O
samples,O
and,O
serum,O
antibody,O
re,O
‐,O
sponses,O
during,O
infection,CAUSE_OF_DEATH
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
:,O
an,O
observational,O
cohort,O
23,NUMBER
Li,O
Z,O
.,O
Yi,O
Y,O
.,O
Luo,PERSON
X,PERSON
.,O
et,O
al,O
.,O
Development,O
and,O
clinical,O
application,O
of,O
a,O
rapid,O
IgM,O
‐,O
IgG,O
combined,O
antibody,O
test,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infec,O
‐,O
tion,O
diagnosis,O
.,O
J,O
24,NUMBER
Cai,PERSON
X,PERSON
.,O
Chen,PERSON
J,PERSON
.,O
Hu,PERSON
J,PERSON
.,O
et,O
al,O
.,O
A,O
peptide,O
‐,O
based,O
magnetic,O
chemiluminescence,O
enzyme,O
immunoassay,O
for,O
serological,O
di,O
‐,O
agnosis,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
covid,O
‐,O
19,NUMBER
),O
.,O
MedRxiv,O
(,O
Pre,O
‐,O
print,O
),O
.,O
25,NUMBER
Gao,O
Y,O
.,O
Yuan,O
Y,O
.,O
Li,PERSON
TT,PERSON
.,O
et,O
al,O
.,O
Evaluation,O
the,O
auxiliary,O
diagnosis,O
value,O
of,O
antibodies,O
assays,O
for,O
detection,O
of,O
novel,O
coro,O
‐,O
navirus,O
(,O
SARS,O
‐,O
Cov,O
‐,O
2,NUMBER
),O
causing,O
an,O
outbreak,O
of,O
pneumonia,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
MedRxiv,O
(,O
Preprint,O
),O
.,O
26,NUMBER
Jia,PERSON
X,PERSON
.,O
Zhang,PERSON
P,PERSON
.,O
Tian,O
Y,O
.,O
et,O
al,O
.,O
Clinical,O
significance,O
of,O
IgM,O
and,O
IgG,O
test,O
for,O
diagnosis,O
of,O
highly,O
suspect,O
‐,O
ed,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
.,O
MedRxiv,O
(,O
Preprint,O
),O
.,O
27,NUMBER
Lin,PERSON
D,PERSON
.,O
Liu,PERSON
L,PERSON
.,O
Zhang,PERSON
M,O
.,O
et,O
al,O
.,O
Evaluations,O
of,O
serological,O
test,O
in,O
the,O
diagnosis,O
of,O
2019,DATE
novel,O
coronavirus,O
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
infections,CAUSE_OF_DEATH
during,O
the,O
COVID,O
‐,O
19,NUMBER
outbreak,O
.,O
MedRxiv,O
(,O
Preprint,O
),O
.,O
28,NUMBER
Liu,PERSON
L,PERSON
.,O
Liu,PERSON
W,PERSON
.,O
Wang,PERSON
S,PERSON
.,O
et,O
al,O
.,O
A,O
preliminary,O
study,O
on,O
serological,O
assay,O
for,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARSCoV,O
‐,O
2,NUMBER
),O
in,O
238,NUMBER
admitted,O
hospital,O
patients,O
.,O
MedRxiv,O
(,O
Preprint,O
),O
.,O
29,NUMBER
Liu,PERSON
Y,PERSON
.,O
Liu,PERSON
Y,PERSON
.,O
Diao,PERSON
B,PERSON
.,O
et,O
al,O
.,O
Diagnostic,O
Indexes,O
of,O
a,O
Rapid,O
IgG,O
/,O
IgM,O
Combined,O
Antibody,O
Test,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
MedRxiv,O
(,O
Preprint,O
),O
.,O
30,NUMBER
Lou,PERSON
B,PERSON
.,O
Li,PERSON
T,PERSON
.,O
Zheng,PERSON
S,O
.,O
et,O
al,O
.,O
Serology,O
characteristics,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
since,O
the,O
exposure,O
and,O
post,O
symptoms,O
onset,O
.,O
MedRxiv,O
31,NUMBER
Pan,O
Y,O
.,O
Li,PERSON
X,PERSON
.,O
Yang,PERSON
G,PERSON
.,O
et,O
al,O
.,O
Serological,O
immunochromatographic,O
approach,O
in,O
di,O
‐,O
agnosis,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infected,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
J,O
32,NUMBER
Zhang,O
P,O
.,O
Gao,PERSON
Q,O
.,O
Wang,PERSON
T,PERSON
.,O
et,O
al,O
.,O
Evaluation,O
of,O
recombinant,O
nucleocapsid,O
and,O
spike,O
proteins,O
for,O
serological,O
diagnosis,O
of,O
novel,O
33,NUMBER
Zhao,PERSON
R,PERSON
.,O
Li,PERSON
M,O
.,O
Song,O
H,O
.,O
et,O
al,O
.,O
Serological,O
diagnostic,O
kit,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
anti,O
‐,O
bodies,O
using,O
CHO,O
‐,O
expressed,O
full,O
‐,O
length,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
S1,O
proteins,O
.,O
34,NUMBER
Long,O
Qx,O
.,O
Deng,PERSON
Hj,PERSON
.,O
Chen,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Antibody,O
responses,O
to,O
SARSCoV,O
‐,O
2,NUMBER
in,O
COVID,O
‐,O
19,NUMBER
patients,O
:,O
the,O
perspective,O
application,O
of,O
serological,O
tests,O
in,O
clinical,O
practice,O
.,O
MedRxiv,O
(,O
Preprint,O
),O
.,O
36,NUMBER
Infantino,PERSON
M,O
.,O
Grossi,PERSON
V,O
.,O
Lari,PERSON
B,PERSON
.,O
et,O
al,O
.,O
Diagnostic,O
accuracy,O
of,O
an,O
automated,O
chemiluminescent,O
immunoassay,O
for,O
anti,O
‐,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
IgM,O
and,O
IgG,O
antibodies,O
:,O
an,O
Italian,NATIONALITY
experience,O
.,O
J,PERSON
Med,PERSON
Virol,PERSON
2020,DATE
;,O
24:24,TIME
.,O
37,NUMBER
Garcia,ORGANIZATION
FP,ORGANIZATION
.,O
Perez,PERSON
Tanoira,PERSON
R,PERSON
.,O
Romanyk,PERSON
Cabrera,PERSON
JP,PERSON
.,O
et,O
al,O
.,O
Rapid,O
diagnosis,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
by,O
detecting,O
IgG,O
and,O
IgM,O
antibodies,O
with,O
an,O
immunochromatographic,O
device,O
:,O
a,O
prospective,O
single,O
‐,O
center,O
study,O
.,O
38,NUMBER
Zhong,PERSON
L,PERSON
.,O
Chuan,PERSON
J,PERSON
.,O
Gong,O
B,O
.,O
et,O
al,O
.,O
Detection,O
of,O
serum,O
IgM,O
and,O
IgG,O
for,O
COVID,O
‐,O
19,NUMBER
diagnosis,O
.,O
Sci,PERSON
China,COUNTRY
Life,O
Sci,O
2020,DATE
;,O
63:777,NUMBER
‐,O
80,NUMBER
.,O
39,NUMBER
Jin,O
Y,O
.,O
Wang,PERSON
M,O
.,O
Zuo,PERSON
Z,PERSON
.,O
et,O
al,O
.,O
Diagnostic,O
value,O
and,O
dynamic,O
variance,O
of,O
serum,O
antibody,O
in,O
coron,O
‐,O
avirus,O
disease,CAUSE_OF_DEATH
2019,DATE
.,O
Int,O
J,O
Infect,O
40,NUMBER
Xie,PERSON
J,PERSON
.,O
Ding,PERSON
C,PERSON
.,O
Li,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Characteristics,O
of,O
patients,O
with,O
coronavirus,O
disease,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
confirmed,O
using,O
an,O
IgM,O
‐,O
IgG,O
antibody,O
test,O
.,O
J,O
Med,O
41,NUMBER
Xiang,PERSON
F,PERSON
.,O
Wang,PERSON
X,O
.,O
He,O
X,O
.,O
et,O
al,O
.,O
Antibody,O
Detection,O
and,O
Dynamic,O
Characteristics,O
in,O
Patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
Clin,O
Infect,O
Dis,O
2020,DATE
;,O
19:19,TIME
.,O
42,NUMBER
Freeman,PERSON
B,O
.,O
Lester,PERSON
S,PERSON
.,O
Mills,PERSON
L,PERSON
.,O
et,O
al,O
.,O
Validation,O
of,O
a,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
spike,O
protein,O
ELISA,O
for,O
use,O
in,O
contact,O
investigations,O
and,O
serosurveil,O
‐,O
lance,O
.,O
43,NUMBER
Paradiso,O
AV,O
.,O
De,PERSON
Summa,PERSON
S,PERSON
.,O
Loconsole,O
D,O
.,O
et,O
al,O
.,O
Clinical,O
meanings,O
of,O
rapid,O
serological,O
assay,O
in,O
patients,O
tested,O
for,O
SARS,O
‐,O
Co2,O
RT,O
‐,O
PCR,O
.,O
44,NUMBER
Imai,PERSON
K,PERSON
.,O
Tabata,PERSON
S,O
.,O
Ikeda,PERSON
M,O
.,O
et,O
al,O
.,O
Clinical,O
evalu,O
‐,O
ation,O
of,O
an,O
immunochromatographic,O
IgM,O
/,O
IgG,O
antibody,O
assay,O
and,O
chest,O
computed,O
tomography,O
for,O
the,O
diagnosis,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
MedRxiv,O
45,NUMBER
Yangchun,ORGANIZATION
F.,ORGANIZATION
Optimize,ORGANIZATION
Clinical,ORGANIZATION
Laboratory,ORGANIZATION
Diagnosis,ORGANIZATION
of,O
COVID,O
‐,O
19,NUMBER
from,O
Suspect,O
Cases,O
by,O
Likelihood,O
Ratio,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
IgM,O
and,O
IgG,O
46,NUMBER
Qian,O
C,O
.,O
Zhou,PERSON
M,O
.,O
Cheng,PERSON
F,PERSON
.,O
et,O
al,O
.,O
Development,O
and,O
Multicenter,O
Performance,O
Evaluation,O
of,O
The,O
First,ORDINAL
Fully,O
Automated,O
SARSCoV,O
‐,O
2,NUMBER
IgM,O
and,O
IgG,O
Immunoassays,O
.,O
MedRxiv,O
(,O
Preprint,O
),O
.,O
47,NUMBER
Ma,O
H,O
.,O
Zeng,PERSON
W,PERSON
.,O
He,O
H,O
.,O
et,O
al,O
.,O
COVID,O
‐,O
19,NUMBER
diagnosis,O
and,O
study,O
of,O
serum,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
specific,O
IgA,O
.,O
IgM,O
and,O
IgG,O
by,O
a,O
quantitative,O
and,O
sensitive,O
immunoassay,O
.,O
MedRxiv,O
(,O
Preprint,O
),O
.,O
48,NUMBER
Perera,ORGANIZATION
RA,ORGANIZATION
.,O
Mok,ORGANIZATION
CK,ORGANIZATION
.,O
Tsang,PERSON
OT,O
.,O
et,O
al,O
.,O
Sero,O
‐,O
logical,O
assays,O
for,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
.,O
March,DATE
49,DATE
Adams,ORGANIZATION
ER,ORGANIZATION
.,O
An,O
R,O
.,O
et,O
al,O
.,O
Evaluation,O
of,O
an,O
‐,O
tibody,O
testing,O
for,O
SARS,O
‐,O
Cov,O
‐,O
2,NUMBER
using,O
ELISA,O
and,O
lateral,O
flow,O
im,O
‐,O
munoassaysP,O
.,O
MedRxiv,O
(,O
Preprint,O
),O
.,O
50,NUMBER
Burbelo,ORGANIZATION
PD,ORGANIZATION
.,O
Riedo,ORGANIZATION
FX,ORGANIZATION
.,O
Mor,O
‐,O
ishima,O
C,O
.,O
et,O
al,O
.,O
Detection,O
of,O
Nucleocapsid,ORGANIZATION
Antibody,ORGANIZATION
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
is,O
More,O
Sensitive,O
than,O
Antibody,O
to,O
Spike,O
Protein,O
in,O
COVID,O
‐,O
19,NUMBER
Pa,STATE_OR_PROVINCE
‐,O
tients,O
.,O
medRxiv,O
(,O
Preprint,O
),O
.,O
51,NUMBER
Lassauniere,ORGANIZATION
R,ORGANIZATION
.,O
Frische,O
A,O
.,O
Harboe,PERSON
ZB,ORGANIZATION
.,O
et,O
al,O
.,O
Evaluation,O
of,O
nine,NUMBER
52,NUMBER
Whitman,PERSON
JD,PERSON
.,O
Hiatt,PERSON
J,PERSON
.,O
Mowery,PERSON
CT,STATE_OR_PROVINCE
.,O
et,O
al,O
.,O
Test,O
performance,O
evaluation,O
of,O
53,NUMBER
Hoffman,PERSON
T,O
.,O
Nissen,PERSON
K,PERSON
.,O
Krambrich,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Evaluation,O
of,O
a,O
COVID,O
‐,O
19,NUMBER
IgM,O
and,O
IgG,O
rapid,O
test,O
;,O
an,O
efficient,O
tool,O
for,O
assessment,O
of,O
past,DATE
exposure,O
54,NUMBER
Dhla,PERSON
M,O
.,O
Boesecke,PERSON
C,PERSON
.,O
Schulte,PERSON
B,O
.,O
et,O
al,O
.,O
Rapid,O
point,O
‐,O
of,O
‐,O
care,O
testing,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
a,O
community,O
screening,O
setting,O
shows,O
low,O
sensitivi,O
‐,O
ty,O
.,O
55,NUMBER
Beeching,ORGANIZATION
NJ,ORGANIZATION
.,O
Fletcher,PERSON
TE,PERSON
.,O
Beadsworth,ORGANIZATION
MBJ,ORGANIZATION
.,O
Covid,O
‐,O
19,NUMBER
:,O
test,O
‐,O
ing,O
times,O
.,O
56,NUMBER
Petherick,O
A.,O
Developing,O
antibody,O
tests,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
57,NUMBER
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
.,O
Advice,O
on,O
the,O
use,O
of,O
point,O
‐,O
of,O
‐,O
care,O
immunodiagnostic,O
tests,O
for,O
COVID,O
‐,O
19,NUMBER
:,O
scientific,O
brief,O
.,O
8,NUMBER
April,DATE
58,DATE
Majumder,ORGANIZATION
MS,ORGANIZATION
.,O
Mandl,ORGANIZATION
KD,ORGANIZATION
.,O
Early,O
in,O
the,O
epidemic,O
:,O
impact,O
of,O
preprints,O
on,O
global,O
discourse,O
about,O
COVID,O
‐,O
19,NUMBER
transmissibility,O
.,O
Lancet,O
Glob,O
